and Human Services (HHS)
EXPIRED
Department of Health and Human Services
Participating Organizations
National Institutes of
Health (NIH), (http://www.nih.gov/)
Components of Participating Organizations
This RFA is developed as a
Roadmap initiative. All NIH Institutes and Centers participate in Roadmap
initiatives. This RFA will be administered by the National Center for Research Resources on behalf of the NIH. http://www.ncrr.nih.gov/.
Title: Institutional Clinical and Translational Science Award
(U54)
Announcement Type
This is a reissue of RFA-RM-06-002,
which was released previously October 12, 2005.
Update: The following update relating to this announcement has been issued:
Request For Applications (RFA) Number: RFA-RM-07-002
Catalog of Federal Domestic Assistance Number(s)
93.389, 93.310
Key Dates
Release Date: August
22, 2006
Letters
of Intent Receipt Date(s): December 18, 2006
Application
Receipt Date: January 17, 2007
Peer
Review Date(s): Summer 2007
Council
Review Date(s): September 2007
Earliest
Anticipated Start Date(s): September 30, 2007
Additional
Information To Be Available Date (URL Activation Date): October 2006
Expiration
Date: January 18, 2007
Due Dates for E.O. 12372
Not Applicable
Additional Overview Content
Executive Summary
Table of Contents
Part I
Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity
Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility
Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and
Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review and
Anticipated Start Dates
1. Letter
of Intent
B. Sending an Application to
the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review
Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review
Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration
Information
1. Award Notices
2. Administrative and National Policy Requirements
A. Cooperative Agreement Terms
and Conditions of Award
1.
Principal Investigator Rights and Responsibilities
2.
NIH Responsibilities
3.
Collaborative Responsibilities
4.
Arbitration Process
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information
- Required Federal Citations
Part II
- Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The National Institutes
of Health (NIH) is engaged in a series of initiatives, collectively known as
the NIH Roadmap for Medical Research (http://nihroadmap.nih.gov/) that promote
clinical and translational investigation and aim to improve health and prevent
disease. The goal of the Institutional Clinical and Translational Science Award
(CTSA) program is to transform the local, regional and national environment for
clinical and translational science, thereby increasing the efficiency and speed
of clinical and translational research. This transformation will be achieved by
creating an academic home, which can be a center, department, or Institute
(C/D/I), comprising faculty and programs that integrate clinical and
translational science across multiple departments, schools, clinical and
research institutes and hospitals. The C/D/I is expected to include faculty
able to conduct original research, develop graduate and postgraduate training
curricula and lead programs that integrate clinical and translational science
across multiple departments, schools, clinical and research institutes and
hospitals.
Definitions: for the purpose of this initiative, Clinical research' comprises studies and trials in human subjects meeting the NIH definition in the PHS 398 instructions. Translational research includes two areas of translation. One is the process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans. The second area of translation concerns research aimed at enhancing the adoption of best practices in the community. The term science' describes the discovery of new knowledge about health and disease prevention, pre-emption, and treatment, as well as methodological research to develop or improve research tools.
Background
Translational and clinical research are critical components for the success of the mission of NIH. Over the years, the science and disciplines underpinning the conduct of translational and clinical research have become increasingly complex. Enhancing the scientific talent pool with the requisite training and intellectual environment needed for further progress may require transformative and innovative approaches. Scientific opportunities made possible by recent advances in genomics, proteomics, informatics, imaging and other novel methodologies, and the need to conduct research in human populations, with the attendant regulatory, organizational, cultural, and sociological complexities, dictate that opportunities for transforming our current approaches be provided to the scientific community at large. The importance of overcoming the barriers to, and enhancing the opportunities for, public trust and participation in clinical and translational research cannot be overemphasized. The NIH's Council of Public Representatives recently explored ways to foster community involvement in clinical research and reported their recommendations (http://copr.nih.gov/reports/October_2004_COPR_WORKSHOP_Proceedings.pdf). Over the years, NIH has supported the conduct of translational and clinical research through multiple separate programs such as General Clinical Research Centers, specialized laboratories and imaging facilities, funds for new and emerging fields such as research informatics, and the training of generations of translational scientists. These investments, however, fall short of recognizing the important linkages between these resources and the growing need to provide sustained interdisciplinary training in a supportive and dedicated academic and intellectual environment beyond that provided by traditional academic structures. A distinct discipline of translational and clinical science is needed to ensure that the rapid and fundamental advances in biomedical and behavioral sciences will be used in patient-oriented research. The discipline requires the development of well structured and well recognized career development pathways that are intertwined with original and fundamental research addressing the methods and approaches to clinical research. This goal may be easiest to reach in an academic home with a dedicated faculty and staff with a transformative vision, mission and strategies.
Specific objectives
The goal of this RFA is to enable the development of the disciplines of clinical and translational science by providing the resources to create an academic home and to benefit translational research. The academic home may be a center/ department/institute, as determined by institutional circumstances that supports the discipline of clinical and translational research. Each individual C/D/I will: provide opportunities and resources for original research on novel methods and approaches to translational and clinical science
The CTSA program is intended to give new opportunities to institutions and their affiliates to be truly innovative in proposals that transform their programs and resources to foster clinical and translational science. The CTSA program will complement the programs of the NIH Institutes and will work in cooperation with other NIH Roadmap activities and other relevant trans-NIH activities.
2. Key Functions of an Institutional CTSA
The CTSA should support the discipline of clinical and translational science and the needs of its researchers. Applicants are encouraged to propose novel concepts, methodologies, and approaches that are integrated into a comprehensive, effective, and efficient researcher-, trainee-, and participant-centered program. Applicants should develop their own list of key functions of the C/D/I. Potential topics include:
The C/D/I should provide clinical research resources including infrastructure and training to various disciplines in its institution (e.g., medicine, dentistry, nursing, pharmacy, public health, biostatistics, epidemiology, bioengineering) for the benefit of researchers, trainees, and research projects across multiple health conditions studied by a wide range of NIH Institutes and Centers. Applications that focus CTSA resources on only a few diseases, specialties, or for limited number of investigators will be returned as unresponsive to this solicitation. Applicants are encouraged to partner with foundations and industry and community organizations as appropriate. In such cases, these partners must agree to follow NIH policies with respect to (1) listing clinical trials at ClinicalTrials.gov; (2) sharing of resources; (3) data sharing and public access and (4) establishing policies in support of investigator academic independence, reporting of patents or patentable concepts, and publication rights. Acknowledging that existing resources vary among applicant institutions, the support requested for each of these components is expected to vary, reflecting current and projected needs. Integration of existing resources and grants into the CTSA activities will be viewed as a strength.
Development of Novel Clinical and Translational Methodologies
Original research on novel methodologies and approaches for translational and clinical sciences will be needed if a C/D/I is to build an environment that sustains intellectual exploration. Faculty members could pursue their funded research in areas that might include, for example, new translational methodologies, developing new phenotyping methods that are more objective and quantifiable, the development of biomarkers for research purposes, research into clinical trial designs, clinical informatics for longitudinal studies, home based research devices and methods, predictive toxicology in human populations, and ethics research specific to populations rather than specific trials.
Pilot and Collaborative Translational and Clinical Studies
New resources are generally required to determine whether the clinical potential of a promising laboratory finding can be realized. Such funds must be available promptly and be accompanied by an organizational structure that allows full compliance with regulatory requirements. An applicant could request support for Pilot and Collaborative clinical research projects that 1) allow clinical and translational trainees or researchers to generate preliminary data for submission of a research grant application; 2) seek to improve clinical design, biostatistics, clinical research ethics, informatics, or regulatory pathways; 3) develop new technologies; or 4) others as defined by the applicant. Pilot and Collaborative projects should, in general, be of sufficient scope to qualify as a stand-alone research effort and should be well integrated into the activities of the CTSA.
Biomedical Informatics
Biomedical Informatics is the cornerstone of communication within C/D/Is and with all collaborating organizations. Applicants should consider both internal, intra-institution and external interoperability to allow for communication among C/D/Is and the necessary research partners of clinical and translational investigators (e.g. government, clinical research networks, pharmaceutical companies, commercial vendors, laboratories, and equipment manufacturers). Biomedical Informatics support is expected to be flexible and innovative. Interoperability, security, workflow, usability and standards are essential areas of work. To facilitate the conduct of research in health care settings and the transfer of research findings into routine care, clinical and translational research must employ applicable standards (e.g., identifiers, vocabularies, transactions, security measures) adopted by the Department of Health and Human Services for use in U.S. health care and public health operations. All human subject data must be handled securely to ensure privacy and confidentiality. Biomedical informatics research activity should be innovative in the development of new tools, methods, and algorithms.
NIH attaches importance to assessments of informatics performance and goal setting across the entire CTSA community. Therefore all Biomedical informatics Directors will participate in the National CTSA Informatics Steering Committee that will be a forum for discussion and agreement on standards, best practices, and/or solutions. The CTSA institution must be committed to working toward adoption and implementation of standards and practices endorsed by the Steering Committee to ensure interoperability for its clinical and translational investigators.
Design, Biostatistics, and Clinical Research Ethics
Design, biostatistics, and clinical research ethics functions support trainees and research teams in research design, analysis, and ethics. In addition, research in these three areas is quite limited so applicants are encouraged to develop innovative and creative research programs that bridge these functions with other CTSA activities. Topics for research might include, for example, limiting risk to participants, preventing bias, improving enrollment, capturing appropriate data, developing design and analysis plans for studies of unique populations or very small numbers of subjects, informed consent, and issues in diseases with limited treatment options.
Regulatory Knowledge and Support
Regulatory Support for research teams will promote the protection of human subjects and facilitate regulatory compliance. Applicants are encouraged to be innovative at all levels of clinical research regulation including, for example, the provision of integrated training, services, or tools for protocol and informed consent authoring and translation, adverse event reporting, safety and regulatory management and compliance, etc. Institutions could develop best practices that reduce or remove institutional impediments to clinical and translational research and, through dissemination and sharing, could enhance inter-institutional collaborations. Regulatory support provided through a CTSA should not take the place of an institutional compliance or enforcement office nor shall it be responsible for Institutional Review Board activities, but should, instead, assist investigators in their documentation requirements. Institutional IRB personnel may interact with the Regulatory support personnel at other CTSA institutions through a National CTSA Regulatory Support Steering Committee to ensure that collaborative clinical and translational research activities are facilitated, whether by policy, procedures, best practices, or other means. The institution should be innovative in developing the Regulatory Support interactions with the IRB and compliance office to facilitate clinical and translational science research without loss of participant protections.
Regulatory Support should include an individual independent of the IRB or compliance office who acts as a sounding board for potential research participants, serves as an advocate for research participants, and works with investigators, trainees, and research teams to ensure that research involving human subjects accords the highest priority to human subject protections.
Participant and Clinical Interactions Resources
Participant and Clinical Interactions resources could provide an environment that promotes participation in clinical and translational research in addition to providing clinical resources for cost-effective human subject interactions. Examples of resources that might be requested include (but are not limited to) the recruitment of research participants, the provision of in-patient, out-patient, or community-based exam rooms, medical vans, temporary research participant recruitment/enrollment sites, research nurses, research coordinators, phlebotomists, scheduling services, and services for research specimen collection and shipping. Applicants should describe a plan to recruit investigators, especially those early in their professional careers, and make the availability of Participant and Clinical Interactions resources known throughout the institution and medical catchments area. Where appropriate, cost recovery for could be sought from funded investigators. General Clinical Research Centers at the institutions of successful applicants and their affiliates will be reconfigured into the CTSA.
Community Engagement and Research
Community outreach could foster collaborative research partnerships and enhance public trust in clinical and translational research, facilitating the recruitment of research participants from the community. Engagement of both the public and community providers, and establishing long-term relationships with community-based groups such as voluntary and professional organizations, schools, women's health groups, faith-based groups, and housing organizations, might be required. Resources that might be requested include community outreach and cultural sensitivity training for institutional clinical and translational researchers, community and provider education and outreach, development of software to facilitate the collaboration of community practitioners, and strategies that allow for two-way communication with, and participation by, community groups. Additional resources that expose scholars and researchers to population and community-based research methods as a supplement to ongoing research efforts in order to enhance applications of science to the general community may prove to be valuable.
Translational Technologies and Resources
These resources could include advanced technologies such as mass spectrometry, imaging, ultrasound, positron emission tomography, gene expression, proteomics, translational cell and gene therapies. Items proposed should be fully justified by local and regional needs. The need for core technologies is likely to vary widely amongst institutions. Standard operating procedures are required as is participation in national or international quality control and standardization efforts where appropriate. The level of support requested must be justified by the projected use by clinical and translational researchers from within and outside the applicant institution(s). Laboratory equipment, supplies, and personnel are all acceptable costs. Cost recovery for core support should be sought from funded investigators. CTSAs will create opportunities for small business partnerships in clinical and translational research for which NIH funding opportunities exist (see Small Business Innovation Research and Small Business Technology Transfer Research (SBIR/STTR) at http://grants1.nih.gov/grants/funding/sbir.htm). CTSA and SBIR/STTR research collaborations would facilitate development from scientific investigations into final products for commercialization with applications for clinical and translational researchers, health care providers, and patient care.
Research Education, Training and Career Development
A key component of a CTSA will be one or more graduate degree-granting and post graduate programs in clinical and translational science that include a knowledge base for clinical and translational researchers, irrespective of their primary interest, degree or discipline. In response to the emergence of interdisciplinary, team-oriented environments, applicants are strongly encouraged to train investigators from diverse disciplines such as medicine, pediatrics, surgery, dentistry, nursing, and pharmacology, as well as study coordinators, project managers, and other key clinical research personnel in a range of topics relevant to clinical and translational science (e.g., clinical research design, epidemiology, biostatistics, pharmacology, biomedical informatics, ethics, behavioral science, engineering, law). Linked U54, K12 and T32 mechanisms, described below, may be used for this purpose.
Research education, training, and career development activities should be structured to promote the recruitment, training, advancement, and retention of new investigators in clinical and translational science careers. Applicants are encouraged to include novel methods and approaches for providing an integrated and flexible research education, predoctoral training, and career development environment that is broad enough in scope to train those interested in careers in multi-disciplinary team-based clinical and translational science, and for the development and improvement of new research methodologies that advance the discipline. Research education, training and career development activities should permeate all aspects of the CTSA program, and trainees and career development scholars should be offered opportunities to utilize all resources and research efforts of the CTSA. Applicants are encouraged to consider ways in which training could be shortened without adversely affecting quality and could explore possibilities of integrating their activities with other curricula in the same or other relevant schools as feasible.
A Research Education component of this RFA could provide didactic courses and/or short term (up to 6 months) research experiences in the fundamental skills of clinical research with the goal of informing clinical research team members about the complex issues of clinical research. Program participants should intend innovative clinical research as their long-term clinical research career plan. The core curriculum could include topics of general interest such as biostatistics, bioethics, clinical trials design, informatics, health data standards and observational study design, Federal policies and regulations that address research with human subjects (e.g., 45CFR46, FDA, INDs, inclusion of women and minorities as well as children in clinical research projects), scientific writing for publication, team leadership and preparation of competitive grant applications. Institutions are encouraged to be imaginative in developing new approaches to education, describing and justifying the proposed period of training and their plans for enrolling trainees. The scope of the curriculum can be flexible to meet the needs of the institution and participants. Inclusion of interdisciplinary approaches is strongly encouraged.
An optional Institutional Predoctoral Research Training (T32 training) component could provide predoctoral students with coursework in clinical and translational research as part of formal advanced degree requirements. Institutional NRSA training grants are designed to allow the director of the program to select the trainees and to provide a curriculum of study and research experiences necessary to provide high quality research training. Appropriate advanced degrees include research doctoral degrees (e.g., PhD, DNSc) in a clinical research-related program and a combined clinical research masters degree given in a combined program with a health professional doctoral degree such as a MD, DDS, DO, DNP, or PharmD. Predoctoral research training must emphasize fundamental research training in clinically related areas of biomedical and behavioral sciences. The training may include, for example, courses in clinical and translational science, biostatistics, research ethics, epidemiology and regulations governing clinical research. The PhD program could provide each trainee with a minimum of three years of full-time research training support. If a combined clinical research master's and health-professional doctoral degree is offered, all institutional requirements for the combined degree must be completed by the trainee by the time the health-professional doctoral degree is completed/conferred. The grant offsets the cost of stipends and tuition support for the appointed trainees. The T32 training component may also offer health-professional predoctoral level students practical experience in clinical research ranging from 2 to 3 months through summer or special rotations each year. The curricula of the rotations should have clearly outlined goals and, ideally, a student should have a research project that will serve as the core of the rotation, and be exposed to many phases of clinical research (design, implementation, data analysis, etc.).
A required Mentored Career Development Component-K12 component will support the research career development of clinical researchers who have recently completed sub-specialty training and who are commencing basic, translational and/or clinical research. The goal of this component is to foster the discipline of clinical research and, by increasing clinical research capacity, to expedite clinical and translational research. The programs will accomplish this through a mentored program, bridging clinical training with research independence. This funding opportunity will use the NIH Mentored Research Career Development Program Award (K12) mechanism. No U54 award for a CTSA will be made without a complementary K12 award.
3. Direction of an Institutional CTSA
The CTSA Governance should define the overall governance and organizational structure of the C/D/I, including the relationships between the CTSA PI and Directors of Key Functions; between institutional resources and CTSA resources; among the schools, departments, specialties, affiliated hospitals, and affiliated independent research institutions that participate in the CTSA; and between the CTSA and outside foundations and/or industry. Administrative policies and procedures should be described, including an evaluation component that will assess the administrative and scientific functioning and accomplishments of the CTSA.
The clinical research experience of the PI, who is the Program Director, should be described, together with his/her involvement in the daily activities of the C/D/I. It is expected this individual would be an established clinician scientist who reports directly to an official with broad trans-institutional authority. The PI has the ultimate responsibility for the implementation and function of the CTSA and is the person with whom the NIH will communicate on broad institutional matters relating to the award. The PI may be assisted by co-Program Director(s) from the same institution or an affiliated institution. Co-Program Director(s) should also be experienced investigators who have administrative skills and backgrounds that complement those of the PI. The amount of effort for the PI and co-Program Directors should be commensurate with the requirements of the positions, and not less than 20% each and preferably sum to not less than 50%. This level of effort is required whether or not salary is requested.
The Directors of the Key Functions of the CTSA should, in general, be senior faculty members who possess the stature, knowledge, authority, leadership, and administrative skills and capabilities necessary to direct the resource, and to speak for the CTSA institution in national forums. Applicants should explain how their clinical and translational science communities would contribute to the selection and allocation of key resources, the implementation and self-evaluation of key functions and the prioritization of use.
It is anticipated that each CTSA will have an External Advisory Committee (EAC) that would meet at least annually to review structure and progress and offer recommendations to the CTSA Director. Potential members of an EAC should not be named and should not be contacted prior to the review of an application.
4. Milestones and Implementation
5. National CTSA Consortium
Under the Cooperative Agreement, a National CTSA Consortium Steering Committee will be established for the CTSA PIs. Additional CTSA sub-committees will be established for each common theme that NIH identifies (e.g., Research Education, Biomedical Informatics, Regulatory Affairs etc). These Steering Committees will meet at least once each year in the Washington, D.C. area and each CTSA should be represented. NIH staff will be active members of each of these Committees and will facilitate communication among the CTSAs with support services, which could include teleconferences, a Listserv, and an interactive website. The first meeting of the Committees will be shortly after issuance of awards. NIH Program Staff will conduct periodic site visits, will review each site's progress in meeting its overall goals, and provide financial oversight of the Program.
The purpose of each of the Steering Committees is to share and disseminate ideas, experience, and tools for ensuring a supportive institutional environment for high-quality clinical and translational research both at the individual institutions and nationally. In addition, Committees will work to develop, adopt, and implement solutions to impediments to collaborative clinical and translational research. The CTSA institutions must be committed to active collaborative participation at the national level and it is through these Steering Committees that common governance will be conducted as their charge will be to decide important common issues and practices among centers, to include topics such as data formats, common consent forms, patient recruitment strategies, course curricula, implementation of common protocols. Letters are required stating that the applicant institutions will work towards adopting and implementing the agreed on policies, procedures, best practices, or other measures established by the National CTSA Consortium Steering Committee.
Further information about expected activities of the each of the Steering Committees will be posted at the CTSA Program web site (http://www.ncrr.nih.gov/clinicaldiscipline.asp)
See Section VIII, Other Information - Required Federal Citations, for policies related to this announcement.
1. Mechanism(s) of Support
This funding opportunity
will use the U54 award mechanism that includes linked K and T components.
Applicants will submit a single unified U54 grant application containing up to
four separate sets of budget pages (the parent U54 activity, K12 and T32
components, as applicable, and a summary budget). If a CTSA application is
selected for funding, the U54, K12 and T32 components will be funded as
separate, yet administratively linked, grants. Applicants may request up to 5
years of support.
The NIH U54 is a cooperative agreement award mechanism. In the cooperative
agreement mechanism, the Principal Investigator retains the primary
responsibility and dominant role for planning, directing, and executing the
proposed project, with NIH staff being substantially involved as a partner with
the Principal Investigator, as described under the Section VI. 2.
Administrative Requirements, "Cooperative Agreement Terms and Conditions
of Award". CTSA awardees will work with NIH staff to ensure that
milestones can be achieved within the budget periods of the award. If
milestones are not met, funding can be limited until the milestones have been
achieved.
As an
applicant, you will be solely responsible for planning, directing, and executing
the proposed project.
Research
Education Component
The
Research Education component of the CTSA application will be funded as part of
the U54 application and is subject to the consideration in the paragraph above.
Predoctoral
Research Training Component-T32
The
optional Predoctoral Research Training -T32 component will be supported under
the auspices of the National Research Service Awards (NRSA) program. All
regulations and policies governing NRSA awards must be followed. Detailed
information regarding NRSA policies and procedures can be found in the NIH Grants Policy Statement at: http://grants.nih.gov/grants/policy/policy.htm.
The T32
component will support research training experiences for at least 4 predoctoral
trainees who are interested in pursuing research careers in multi-disciplinary
clinical and translational science. Only predoctoral NRSA positions may be
requested and supported through the T32 part of this initiative. Trainees are
selected by a Program Director normally for 12-month appointment periods with
support for additional years based on satisfactory progress and the continued
availability of funds. Short-term, health-professional predoctoral trainees
such as MD, DDS, DO, DNP, PharmDs will be funded on pro-rated stipends for the
2-3 months they are in the program, based on the 12-month predoctoral stipend
level. The institution may supplement the NIH stipend up to a level that is
consistent with the institution's scale from non-Federal sources only. It is
expected that total stipends must be consistent with the level of effort, with
the established stipend structure at the institution, and with stipends
actually provided by the institution from its own funds to other staff members
of equivalent qualifications, rank, and responsibilities in the department
concerned.
See Section IV.5. Funding Restrictions, for a description of Allowable Costs.
Mentored Career Development Component-K12
The mentored career development component-K12 will provide for a minimum of two years and a maximum of five years of consecutive funding for each CR Scholar, consisting of consecutive 12-month appointments. In general, 75 percent of the CR Scholars' full-time professional effort must be devoted to the K12 Program. However, certain clinical specialties can have less than 75 percent, but no less than 50 percent, protected time for this Program if sufficiently justified and programmatically approved (for example, surgical specialties requiring 50 percent direct patient care time to keep up surgical skills). The remaining effort must be devoted to activities related to the development of a successful clinical and translational research career. The salary must be consistent both with the established salary structure at the institution and salaries actually provided by the institution from its own funds to other staff members of equivalent qualifications, rank, and responsibilities. The award will support the salary, fringe benefits, and research costs for scholars planning research careers in multi-disciplinary clinical and translational science. Individual scholars are eligible for up to $160,000 salary plus fringe benefits based on the sponsoring institution's rate per year. If full-time, 12-month salaries are not currently paid to comparable staff members, the proposed salary must be appropriately related to the existing salary structure.
The sponsoring institution may supplement the NIH salary contribution up to a level that is consistent with the institution's salary scale; however, supplementation may not be from other Federal funds unless specifically authorized by the Federal program from which such funds are derived. In no case may PHS funds be used for salary supplementation. Institutional supplementation must not require extra duties or responsibilities that would interfere with the purpose of the K12 component.
Under expanded authorities, however, institutions may rebudget funds within the total costs awarded to cover salaries consistent with the institution's salary scale. The total salary, however, may not exceed the legislated maximum (http://grants.nih.gov/grants/policy/salcap_summary.htm).
Effective for all competing research project grant applications submitted for the February 1, 2004, deadlines and beyond, mentored career award recipients, including K12 scholars) in the last 2 years of career award support may reduce effort on the career award to a minimum of 50% and hold concurrent support from their career award and a competing NIH research grant when recognized as a Principal Investigator or subproject Director. This new policy can be found at the following website: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-007.html.
Pilot and Feasibility Project Support
K12 Scholars may receive funds to support pilot research projects and career development activities. This support will range from $25,000 to $50,000 per project per year to cover the following expenses: (a) tuition and fees related to career development; (b) research expenses, such as supplies, equipment and technical personnel; (c) travel to research meeting, workshops, or training; (d) statistical services including personnel and computer time.
Ancillary Personnel Support
Salary for mentors, secretarial and administrative assistance, etc., is not an allowed cost as part of the K12 or T32 components. Administrative support could be included as part of the U54 component if sufficiently justified.
Facilities and Administrative Costs
These costs, which were formerly called indirect costs, will be reimbursed at eight percent of modified total direct costs, or the actual indirect cost rate, whichever is less.
This funding opportunity uses the just-in-time budget concepts. It also uses the non-modular budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/phs398/phs398.html). A detailed categorical budget for the "Initial Budget Period" and the "Entire Proposed Period of Support" is to be submitted with the application.
Future Solicitations:
The NIH
intends to issue solicitations for additional CTSAs in future years.
2. Funds Available
The total funds available for the new awards are
approximately $38 million. Up to 8 awards are anticipated from this
solicitation with an anticipated start date of September 30, 2007.
Awards will vary in size due to the consolidation of multiple programs within the CTSA program. Applicants may request total costs up to $6 million annually in addition to the combined current total costs of certain NIH awards (NCRR K12, K30, M01 and Roadmap T32 and K12) held by the applicant institution and its affiliates. When summing the awards for NCRR M01, K12, K30 and Roadmap K12 and T32 to calculate the base above which CTSA funding may be requested, the amounts that should be used are the Approved Budgets from the latest Notice of Grant Award prior to October 1, 2006. Applicants whose NCRR M01, K12, K30 and Roadmap K12 or T32 awards end in the interval between a first and revised submission should contact NCRR Program Staff to ascertain the budget base for the revised application. If the application is successful, all of the above listed awards at each participating institution will be reconfigured into the CTSA program. The CTSA policy and guidelines for patient care restricted funds will replace those of other mechanisms and these new guidelines will be defined in the Notice of Grant Award for the CTSA. Institutions without the above awards may request up to $6 million annually in total costs.
An applicant may request a project period of up to 5 years. Although the financial plans of the NIH Roadmap and NCRR provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. Direct CTSA costs should not be used for institutional infrastructure that is supported through F & A costs. Annual increments and cost-of-living adjustments will follow NIH guidelines.
Applicants for CTSA awards in excess of $4M total costs above the combined current total costs of certain NIH awards should meet the following additional requirements:
3. Special Consideration
NOTE:
Notice NIH NOT-RR-06-001 provides information on changes to the NCRR General Clinical Research Centers
(M01) program. Additionally, all NCRR K12, the NCRR-managed trans-NIH K30, and
Roadmap Multidisciplinary Clinical Research Career Development Programs (K12)
and Predoctoral Clinical Research Training Programs (T32) held by successful
applicant institutions and their affiliates will transition into a CTSA.
Section III. Eligibility Information
1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an)
application(s) if your organization has any of the following characteristics:
Domestic institutions including universities, academic health centers, or other research organizations conducting translational and clinical research are eligible, with the following requirements. Because the Institutional CTSA program is focused on the development of a rigorous and robust academic discipline of clinical and translational science, the applicant institution(s) must include a graduate school accredited to award higher degrees in clinical research. Examples of acceptable higher degrees include M.S. and Ph. D. in topics such as Clinical Research, Public Health, Pharmacology, Nursing and Epidemiology. Partnerships among schools of medicine, dentistry, nursing, pharmacy, osteopathy, public health, engineering and other clinically-related institutions are strongly encouraged, as is the inclusion of other relevant clinical research entities and organizations. The CTSA institution(s) is expected to form an integrated institutional home that includes faculty committed to developing the discipline of clinical and translational science that will transcend multiple departments, schools, clinical and research institutes and hospitals. Therefore, an institution may submit, or be part of, only a single application in response to this RFA. Multiple applications from different divisions, faculties, centers, schools, etc. of the same university or medical school will be returned without further consideration by the NIH. Potential applicants whose existing affiliations will be disrupted by this rule must contact NIH Program Staff to determine whether they may be eligible for a waiver of the restriction on grounds such as the affiliation is supported through active NIH Roadmap Training (T32), Career Development (K12) awards, or long-term affiliations. Foreign institutions and foreign components of applications are not allowed. Applications from ineligible institutions will not be reviewed. The application must include clear detailed evidence of significant institutional commitment.
An organization is eligible to hold a CTSA or an M01 award, but not both. At the time of the CTSA award, current NCRR K12, K30, M01 awards, and NIH Clinical Roadmap K12 and T32 (Predoctoral Clinical Research Training Program) awards to the institution(s) or affiliated institutions will be relinquished and any remaining funds, including un-obligated balances, will be transferred into the new CTSA award. If the applicant is unsuccessful, the institution(s) retains the current awards for the awarded project period.
1.B. Eligible Individuals
1.B.1. Eligible Principal Investigators
The Principal Investigator is expected to have the institutional authority to direct the C/D/I or other entity that comprises the proposed institutional home for clinical and translational science. The PI should have direct knowledge and hands-on involvement in the daily activities of the C/D/I. It is expected this individual would be an established clinician scientist who reports directly to an official with broad trans-institutional authority. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
1.B.2. Eligible Key Function Directors
All Directors of Key Functions and any co-Program Directors should have the necessary recent clinical and translational research background and administrative qualifications and experience to provide scientific leadership, management, and coordination of their respective programs or components. The Principal Investigator of the CTSA will coordinate the activities of all the Directors of Key Functions.
A T32 Program Director must be an established researcher with acknowledged accomplishments in clinical and translational science research, and should be capable of providing both administrative and scientific leadership to the proposed multi-disciplinary training program. The training Program Director will be responsible for planning, directing, and executing the research training program and the selection, appropriate supervision/mentorship, and evaluation of the trainees progress.
The Program Director for the K12 component must be an established investigator with the scientific and administrative skills, knowledge and leadership to coordinate and supervise the mentored career development program. The individual must be a senior faculty member or director of research with extensive expertise recruiting, advancing, and retaining individuals in clinical and translational science careers.
1.B.3. Eligible Research Education, Training and Career Development trainees, scholars and mentors
Research Education Component
Clinical research is multidisciplinary so participants in this program should represent diverse academic backgrounds with the potential for benefit from a core curriculum for clinical research. Interactions during the early years of career development may serve to enhance the team approach necessary to meet the multidisciplinary challenges of clinical research. Individuals supported by NIH training and career development mechanisms (K, T, or F awards) may receive, and indeed are encouraged to receive, educational experiences supported by the research education component, as participants, but may not receive salary or stipend supplementation from the CTSA research education component.
Predoctoral Research Training Component-T32 Eligibility
At the time of appointment to the training program, individuals selected to participate in the training program must be citizens or non-citizen nationals of the United States, or have been lawfully admitted to the United States for permanent residence and have in their possession an Alien Registration Receipt Card (I-151 or I-551) or other legal verification of admission for permanent residence. Non-citizen nationals are persons born in lands that are not States but are under U.S. sovereignty, jurisdiction, or administration (e.g., American Samoa). Individuals on temporary or student visas are not eligible for NRSA support. In addition, trainees must be able to commit full-time effort in the program at the time of appointment.
Predoctoral trainees must have received a baccalaureate degree by the beginning date of their NRSA trainee appointment, and must be training at a post-baccalaureate level and enrolled in a program leading to a Ph.D. in a clinical research-related doctoral degree program, or a combined doctoral level professional degree plus a clinical research-related advanced degree, such as a MD, DDS, DO, DNP, PharmD/MS or MD, DDS, DO, DNP, PharmD/PhD. NRSA traineeships are not provided for study leading to a MD, DO, DDS, DNP, PharmD or other similar professional clinical degrees, or a master's degree that is not pursued in a combined program with a professional level doctorate. Individuals currently supported by other Federal funds are not eligible for trainee support from the T32 program at the same time.
Trainees are customarily appointed for full-time, 12-month continuous periods. No trainee may be appointed for less than nine months without prior approval of the NIH program staff except for predoctoral health-professional students that are participating in approved, formal short-term research training experiences. All trainees are required to pursue their research training on a full-time basis, normally defined as 40 hours per week or as specified by the sponsoring institution in accordance with its own policies. An individual trainee may receive no more than five years of NRSA support in the aggregate at the predoctoral level, including any combination of support from institutional training grants and individual fellowship awards. Exceptions to this limitation require a waiver from the director of the funding Institute based on a review of the justification provided by the awardee, and must be submitted for prior written approval.
Mentored Career Development Component-K12 Scholar Eligibility
Only U.S. citizens or non-citizen nationals, or an individual lawfully admitted for permanent residence who possesses an Alien Registration Receipt Card (I-151 or I-551), or some other verification of legal admission as a permanent resident prior to appointment, are eligible to become K12 scholars. Non-citizen nationals, although not U.S. citizens, owe permanent allegiance to the U.S. They are usually born in lands that are not states but are under U.S. sovereignty, jurisdiction, or administration. Individuals on temporary or student visas are not eligible.
K12 scholars must have a research or health-professional doctoral degree or its equivalent. Candidates must be able to commit a minimum of 75 percent of full-time professional effort conducting research career development and research activities associated with the program. The remaining 25 percent effort can be divided among other research, clinical and teaching activities only if these activities are consistent with the proposed goals of the K12 program. The eligibility of potential candidates holding VA appointments should be confirmed with NIH staff responsible for the fiscal management of the award prior to the individual being appointed to the program.
K12 scholars may not simultaneously submit or have pending an application for any other PHS mentored career development award (e.g., K07, K08, K22, K23), that duplicates any of the provisions of the K12 program. Former or current principal investigators on any NIH research project grant (this does not include NIH Small Grants (R03) or Exploratory/ Developmental (R21) grants or their equivalents) or equivalent non-PHS peer reviewed research grants that are over $100,000 direct costs per year, or project leaders on sub-projects of program project (P01) or center grants (P50) are NOT eligible to participate as K12 scholars.
K12 Mentor Eligibility
The K12 component of the application must identify a core group of primary sponsor/mentors for the career development program. Each mentor together with the scholar will be responsible for the planning, direction, and execution of each career development plan and research project. Mentors must be recognized as accomplished investigators in clinical and translational research and have a track record of success in training new investigators and fostering their transition to independence. Mentors should have sufficient independent research support to cover the costs of the proposed research project in excess of the allowable costs of the K12 and CTSA. The use of co-mentors to achieve the goals of the program is encouraged. Where feasible, women, minority individuals and individuals with disabilities should be involved as mentors to serve as role models.
2. Cost Sharing or Matching
Significant institutional commitment is required by the applicant institution(s). This may take the form of office, laboratory, or clinical space; personnel; equipment; integration of other clinical grants or centers; other resources; or dollars. There is no requirement for cost sharing or matching for institutional eligibility.
The most current Grants Policy Statement can be found at: http://grants.nih.gov/grants/policy/nihgps_2003/nihgps_Part2.htm#matching_or_cost_sharing.
3. Other-Special Eligibility Criteria
Not
applicable
Section
IV. Application and Submission Information
1. Address to Request Application Information
The PHS 398 application
instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of
the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: [email protected].
Telecommunications for
the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be
prepared using the most current PHS 398 research grant application instructions
and forms. Applications must have a D&B Data Universal Numbering System
(DUNS) number as the universal identifier when applying for Federal grants or
cooperative agreements. The D&B number can be obtained by calling (866) 705-5711
or through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of the face page of the PHS 398
form.
The title and number of this funding opportunity must
be typed on line 2 of the face page of the application form and the YES box
must be checked.
Special Program Requirements
The NIH recognizes that individual institutions will be able to respond in different ways to the opportunities presented by this RFA. Applicants are strongly encouraged to contact NIH program staff early in the application process and they should have a thorough understanding of the intent and expectations of this RFA before developing an application. A pre-submission videoconference will be conducted on Thursday October 5, 2006, between 2:00 and 4:00 pm at which NCRR and other NIH staff will explain the goals and objectives of the CTSA program and answer questions. All prospective applicants are invited to view the meeting through videoconference or videocast (webcast). Additional information on videocasting will be available at (http://www.ncrr.nih.gov/clinicaldiscipline.asp) and the meeting videocast will be archived at videocast.nih.gov. A Frequently Asked Questions website is available (http://www.ncrr.nih.gov/clinicaldiscipline.asp). A listserv (CTSA-L; http://list.nih.gov/cgi-bin/show_list_archives) will be used to notify applicants of the web cast and any changes to the FAQ list.
Applicants should address the key functions proposed for their CTSA using the FORMAT OF THE APPLICATION following this section. All information must be contained within the body of the application; appendices are not allowed.
1. Overall approach.
Applicants should describe how the CTSA will transform clinical and translational research at their institutions. They should describe the components and functions of a C/D/I with reference to:
Progress toward projects' goals will be considered when renewal applications are re-competed. Applicants are requested to relate the goals described above to the Key Functions in their application and, where appropriate, to the examples of CTSA activities listed below.
2. Governance.
Applicants should describe:
The rationale for these approaches should be described. Applicants describing an External Advisory Committee should not contact potential members until after an award has been made. Names of potential members must not be listed in the application.
Applicants should indicate the level of authority that the institution(s) will delegate to CTSA personnel when they participate on the institution(s)'s behalf in developing trans-CTSA policies, procedures, or best practices. They should also indicate the institution's willingness to adopt and implement these practices.
3. Development of Novel Clinical and Translational Methodologies and Pilot and Collaborative Translational and Clinical Studies.
Applicants should describe the means for selecting Novel Clinical and Translational Methodologies that will receive core support, together with a plan for their governance, operation and evaluation. The description of Pilot and Collaborative Project support should include the scope; eligibility requirements; the limit on the dollars available and the number of years of support per project; the submission, review, and selection criteria and process; oversight and evaluation procedures; and assurances that all projects supported from this grant will comply fully with all applicable Federal policies, rules, and guidelines for research involving human subjects.
4. Biomedical Informatics.
Applicants should describe:
Biomedical Informatics is expected to be the subject of an overall NIH CSTA Informatics Steering Committee that ensures interoperability between the CTSA institutions and with their external partners. National issues impacting clinical and translational science research will be addressed jointly by the NIH CTSA Informatics Steering Committee, working with national leaders in healthcare informatics technology, national standards organizations, and the government.
5. Design, Biostatistics and Clinical Research Ethics.
Applicants should describe:
6. Regulatory Knowledge and Support.
Applicants should describe:
7. Participant and Clinical Interactions Resources (PCIR).
Applicants should describe and justify:
8. Community Engagement and Research
Descriptions of Community Engagement could include how the institution will involve the community in setting research priorities that directly affect patients, innovative ways to engage community members in mentoring processes, partnerships in clinical and translational research, and collaborations to enhance research perspectives (e.g., health disparity research), public trust, and recruitment for clinical and translational research. Additional topics could include plans for: two-way communication with relevant community groups; outreach through community practitioners, including means to secure their participation, and plans for training CTSA researchers, trainees and scholars in community outreach, cultural sensitivity, and population and community-based research methods.
9. Translational Technologies and Resources.
Applicants should describe:
10. Research Education, Training and Career Development.
Applicants should describe:
Evaluation and Tracking
The application should describe a strong evaluation and tracking plan for all Research education, training and career development activities. The plan should include the review of the effectiveness of all aspects of the program (including curriculum development, training faculty, Program Directors). Program Directors are encouraged to develop plans to obtain feedback from current and former trainees to help identify weaknesses in the training program and to provide suggestions for program improvements. The application should describe plans for a research education, training and career development program advisory committee.
The NIH may, in the future, request information about trainees for program evaluation purposes. In addition, institution(s) with other clinical or translational training and career programs must provide strong evidence that this CTSA Program will improve existing clinical and translational research career development and mentoring programs (including but not limited to individuals supported via NIH T32, K12, K23, K24 and K30 grants) and how they will interact with the CTSA program.
Training in the Responsible Conduct of Research
Applications must include a description of programs designed to provide formal and informal instruction in scientific integrity or the responsible conduct of research relevant to all CTSA activities. Applications without plans for instruction in the responsible conduct of research for each component will be considered incomplete and may be returned to the applicant without review.
Although the NIH does not establish specific curricula or formal requirements, all programs are encouraged to consider instruction in the following areas: conflict of interest, responsible authorship, policies for handling misconduct, data management, data sharing, and policies regarding the use of human and animal subjects. Within the context of training in scientific integrity, it is also beneficial to discuss the relationship and the specific responsibilities of the institution and the predoctoral trainees appointed to the program. Plans must address the subject matter of the instruction, the format of the instruction, the degree of training faculty participation, trainee attendance, and the frequency of instruction. The rationale for the proposed plan of instruction must be provided.
Program reports on the type of instruction provided, topics covered, and other relevant information, such as attendance by trainees and faculty participation, must be included in progress reports and future competing continuations. The NIH encourages institutions to provide instruction in the responsible conduct of research to all graduate and postdoctoral students and research staff regardless of their source of support.
Please see http://www.nih.gov/sigs/bioethics/researchethics.html for additional guidance.
Minority Recruitment and Retention Plan
The NIH remains strongly committed to increasing the participation of individuals from underrepresented minority groups and individuals with disabilities in biomedical and behavioral research. Institutions are encouraged to identify participants who will increase diversity on a national or institutional basis. The following groups have been identified as underrepresented in biomedical and behavioral research nationally: African Americans, Hispanic Americans, Native Americans, Alaska Natives, and Pacific Islanders. Applicants must describe their program plans and efforts to recruit such individuals, as well as their success in the retention, and graduation of these individuals. All applications must contain plans to demonstrate commitment and proactive recruitment efforts. The review panel's evaluation will be included in an administrative note in the summary statement. If the plan or the record of minority recruitment and retention is judged to be unacceptable, funding will be withheld until a revised plan (and report) that addresses the deficiencies is received. NIH Staff will determine whether amended plans and reports submitted after the initial review are acceptable.
Recruitment and Retention Plan to Enhance Diversity:
The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences workforce. The NIH expects efforts to diversify the workforce to lead to the recruitment of the most talented researchers from all groups; to improve the quality of the educational and training environment; to balance and broaden the perspective in setting research priorities; to improve the ability to recruit subjects from diverse backgrounds into clinical research protocols; and to improve the Nation s capacity to address and eliminate health disparities.
Accordingly the NIH continues to encourage institutions to diversify their student and faculty populations and thus to increase the participation of individuals currently underrepresented in the biomedical, clinical, behavioral, and social sciences such as: individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have inhibited their ability to pursue a career in health-related research. Institutions are encouraged to identify candidates who will increase diversity on a national or institutional basis. The NIH is particularly interested in encouraging the recruitment and retention of the following classes of candidates:
A. Individuals from racial and ethnic groups that have been shown by the National Science Foundation to be underrepresented in health-related sciences on a national basis (see http://www.nsf.gov/statistics/) In addition, it is recognized that under-representation can vary from setting to setting and individuals from racial or ethnic groups that can be convincingly demonstrated to be underrepresented by the grantee institution should be encouraged to participate in this program.
B. Individuals with disabilities, who are defined as those with a physical or mental impairment that substantially limits one or more major life activities.
C. Individuals from disadvantaged backgrounds who are defined as:
1. Individuals who come from a family with an annual income below established low-income thresholds. These thresholds are based on family size, published by the U.S. Bureau of the Census; adjusted annually for changes in the Consumer Price Index; and adjusted by the Secretary for use in all health professions programs. The Secretary periodically publishes these income levels at http://aspe.hhs.gov/poverty/indix.shtml. For individuals from low income backgrounds, the institution must be able to demonstrate that such candidates have qualified for Federal disadvantaged assistance or they have received any of the following student loans: Health Professional Student Loans (HPSL), Loans for Disadvantaged Student Program, or they have received scholarships from the U.S. Department of Health and Human Services under the Scholarship for Individuals with Exceptional Financial Need.
2. Individuals who come from a social, cultural, or educational environment such as that found in certain rural or inner-city environments that have demonstrably and recently directly inhibited the individual from obtaining the knowledge, skills, and abilities necessary to develop and participate in a research career. Recruitment and retention plans related to a disadvantaged background are most applicable to high school and perhaps undergraduate candidates, but would be more difficult to justify for individuals beyond that level of achievement.
Competing continuation and non-competing applications must include a detailed account of experiences in recruiting individuals from underrepresented groups during the previous funding period. Information must be included on successful and unsuccessful recruitment strategies including aggregate information on the distribution of:
For those trainees who were enrolled in the academic program, the report should include information about the duration of research training and whether those trainees finished their training in good standing.
Peer reviewers will separately evaluate the recruitment and retention plan to enhance diversity after the overall score has been determined. Reviewers will examine the strategies to be used in the recruitment and retention of individuals from underrepresented groups. The review panel’s evaluation will be included in an administrative note in the summary statement. If the recruitment and retention plan to enhance diversity is judged to be unacceptable, funding will be withheld until a revised plan (and report) that addresses the deficiencies is received. Staff within the NIH awarding component, with guidance from the appropriate national advisory committee or council as needed, will determine whether amended plans and reports submitted after the initial review are acceptable.
This RFA requires all applicants to submit a recruitment and retention plan to enhance diversity. If an application is received without a plan, the application will be considered incomplete and will not be reviewed.
Research Education Component
Applicants should describe the content of the proposed courses, their potential benefits to the participants and how continuation and/or expansion of an existing program or development of a new program will benefit clinical and translational science training at the institution. The commitment of the applicant institution and the faculty to providing didactic and mentoring experiences should be described, together with the pool of potential participants and information about the types of prior clinical and research training.
Predoctoral Research Training Component-T32
1. Proposed Training Program
The training program must be described in detail, including the objectives, design and courses planned for the trainees. Within the 40 hours per week training period, provide the plan for the proposed research training and the role of the Program Director and faculty serving as mentors to the trainees. Explain how the trainees will be engaged on research projects and the relationship of such activities to the overall goals of the education and career development program of the cooperative agreement and the career goals of the trainees. Trainees supported through the T32 mechanism are expected to be working in a clinical research-related area.
2. Institutional Commitment
The administration of the applicant institution as well as all participating units and departments should indicate, in the application, their support for the goals of the training program. Describe support (financial or otherwise) that the institution will provide for the proposed predoctoral training program. This could include, for example, space, shared laboratory facilities and equipment, funds for curriculum development, release time for the Program Director or participating faculty, support for additional trainees in the program, or any other creative mechanisms to improve the climate for the establishment and growth of the training program (e.g., Core facilities).
3. Faculty and Mentors
Describe the plans for mentoring of the trainees selected for the program. Include information about past mentoring experiences and active research programs being conducted by the proposed mentors and faculty involved in the proposed training program. Describe collaborative arrangements with mentors and students which will enhance the training program and broaden the training experiences involved in the clinical and translations science program.
Additional NRSA information and instructions are available at: http://grants.nih.gov/grants/funding/phs398/phs398.html.
Mentored Career Development Component-K12
This section should begin with an overview of the proposed program and describe:
11. Tracking and Evaluation Plan.
The proposal should first include a detailed self-evaluation plan to assess implementation of the short-term and long-term CTSA goals, including implementing program activities and tracking trainees and scholars and their mentors, their pilot projects, and their involvement with multidisciplinary team research. For each proposed key function, the plan should include the objectives of the evaluation or tracking activities, the principal measures or indicators, and potential data sources. Applicants should describe procedures to obtain IRB approval and informed consent from trainees, scholars, and mentors in evaluation data collection efforts, if necessary. Listed below are examples of evaluation objectives for illustrative key functions:
CTSA Key Functions:
Assess the demand for, and effectiveness of, any Novel Clinical and Translational Methodologies, Pilot and Collaborative Translational and Clinical Studies, Community Engagement and Translational Technologies and Resources
Biomedical Informatics
Design, Biostatistics and Clinical Research Ethics
Regulatory Knowledge and Support
Participant and Clinical Interactions Resources
Research Education, Training and Career Development
Overall Operational Functions
To support this effort, the NIH will request that grantees participate in the planning, design, and conduct of the national evaluation and that grantees plan local evaluation activities that will provide data necessary for both their own evaluation and the national evaluation.
12. Milestones and Implementation Plan.
13. Required Institutional Letters.
Applicants should provide letters from the appropriate high-ranking institutional official(s) from the parent institution(s) and its affiliates that:
Separate letter(s) co-signed by the CTSA Principal Investigator and the Principal Investigator of each of the NIH-funded NCRR, Roadmap, and Trans-NIH awards listed above to acknowledge that each of these grants will be relinquished in the event this application is funded. These letters must be also co-signed by the appropriate business officials of each specific award and of this CTSA application. Applications with unacceptable letters will not be reviewed.
Separate letter(s) co-signed by the PI and all the appropriate technology transfer offices that they will abide by the data and resource sharing plans specified in the application. Applications with unacceptable letters will not be reviewed or awarded.
Format of the Application
The instructions in the Form PHS 398 do not fully apply to the special needs of this grant application. Therefore, follow the modified instructions below in preparing an application for an Institutional Clinical and Translational Science Award. The application should be organized as follows (when following this format, applicants should refer regularly to those sections of this announcement that delineate Special Programmatic Requirements and Review Criteria ):
A. Face Page: Use Form Page 1 of the PHS 398. On Line 1, include the title that best represents the nature of the Institutional CTSA Program. On Line 2, provide the number of this Request for Applications, RFA-RM06-00XX, and the RFA title "Institutional Clinical and Translational Science Awards." The budget figures on this page should be taken from the consolidated program budget (see below).
B. Description, Performance Sites, and Key Personnel. Key Personnel include the Principal Investigator, co- Program Director(s), Directors(s) and co- Directors(s) of key resources, and other key professional and administrative members of this Program. Do not include trainees, mentors, or external advisory committee members. Only include named individuals for whom salary support is requested in the application.
C. Table of Contents
D. Detailed Budget Page for Initial Budget Period and Entire Proposed Period of Support: Four sets of budget pages (Form pages 4 & 5) are required that together incorporate all the proposed activities of the CTSA. The first set is for the U54 budget that contains the majority of the items in the program. Justification for equipment, personnel and supplies should be included in this set of budget pages. The second set for a Career Development (K12) component should provide information reflecting the administrative expenses anticipated for the K12 component, which includes: Personnel, supplies, travel expenses for the Program Director to attend relevant scientific meetings for the initial year. Include under Other Expenses: scholar costs, which includes planned salaries, fringe benefits, and research expenses for the number of scholars being proposed in the program. If a T32 pre-doctoral component is included to pay for pre-doctoral trainee stipends, travel, and training-related expenses per NRSA guidelines, this budget should be submitted on Kirschstein-NRSA Substitute Form Pages. The fourth set, showing the composite budget, should include stipends in the personnel category and all other training costs in the other expenses category. Budget items should be requested for 12 months; NCRR will prorate these items accordingly at the time of award. To calculate the maximum allowed funding amount, add the costs of your most recent Notice of Grant Award budgets for all applicable components. Applicants are requested to copy their budget items into the spreadsheet provided on the CTSA program website (http://www.ncrr.nih.gov/clinicaldiscipline.asp).
E. Biographical Sketches and research support in standard NIH format for Program Director, co-director(s), other listed key professional and administrative members of this Program, and named members of significant internal committees. Do not include biographical sketches for trainees or external advisory committee members, or those who are not directly involved in the CTSA.
F. Institutional Clinical and Translational Science Award Program: The application must present all the proposed activities of the CTSA within the page limits shown below. Note that these are upper limits: applicants are urged to be concise and to present information as tables where possible. Applicants are strongly discouraged from giving programmatic URL's in their applications, and reviewers are not obligated to view applicant's web sites to review existing public information. No appendices are allowed. References are not included in the page limits and may be cited in the appropriate sections of the application or in Section H. The information should be arranged as follows:
(1) Overall Integrated Approach/Governance (25 pages)
* Approach/Meeting the Intent of this Initiative
* Participating Institution(s)
* Innovation
* Institutional Commitment
* Governance
* National Collaboration, Sharing, and Dissemination Plan
Note: this section should include a description of Resources and Environment, replacing the corresponding page in PHS 398.
(2) Program functions (15 pages each unless noted)
* Development of Novel Clinical and Translational Methodologies
* Pilot and Collaborative Translational and Clinical Studies
* Biomedical Informatics
* Design, Biostatistics, and Clinical Research Ethics
* Regulatory Knowledge and Support
* Participant and Clinical Interaction Resources
* Community Engagement and Research
* Translational Technologies and Resources
* Research Education, Training and Career Development (25 pages)
* Other program functions (up to 15 pages per function; 50 pages total)
(3) Tracking and Evaluation (20 pages)
(4) Implementation Phase and Milestones (10 pages)
(5) Tables (50 pages maximum). The organization and content of the tables is left up to the applicant; however, summary and graphical displays are encouraged. Organization tables can be distributed throughout the application in proximity to their respective sections. Programs may wish to comment on the past and current funding for, and productivity of:
* Clinical and translational research.
* Clinical and translational research infrastructure. This table should include all shared clinical and translational research services and facilities within the institution(s) (e.g., GCRCs, technology cores, centers, etc.).
* Training and career development programs relevant to clinical and translational research (e.g., K30s, T32s, R25s, K12s, GCRCs, School of Public Health, Degree Programs, etc.)
* The program members and potential members, including their expertise and training record
* Biomedical Informatics resources, including critical information systems and current efforts at providing an interoperable environment.
G. Literature cited
H. Required Institutional Letters (see Special Program Requirements above)
I. Human Subjects
J. Patient Care Rate Agreement (if applicable)
K. Vertebrate Animals
L. Checklist
Note: Appendices are not allowed.
Resubmission
(formerly Revised ) Applications All resubmission
applications must include an Introduction to a Resubmission Application, not to
exceed three pages. List each area of concern noted in the Summary Statement
for the previous application, and summarize clearly the changes that have been
made in the resubmission application. Do not include an extensive description
of each change in the introduction. In the body of the application, highlight
paragraphs with significant changes by changing the typography. If the changes
are so extensive as to include most of the text, this exception should be
explained in the Introduction to the Resubmission Application. Do not underline
or shade changes.
3. Submission Dates and Times
Applications must be
received on or before the receipt date described below (Section
IV.3.A). Submission times N/A.
3.A.
Receipt, Review and Anticipated Start Dates
Letters of Intent
Receipt Date(s): December 18,
2006
Application
Receipt Date(s): January 17,
2007
Peer Review Date(s): Summer 2007
Council Review
Date(s): September 2007
Earliest
Anticipated Start Date(s): September 30, 2007
3.A.1. Letter of Intent
Prospective applicants
are asked to submit a letter of intent that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed
at the beginning of this document.
The letter of intent
should be sent by e-mail to:
Dr. Anthony Hayward
Division for Clinical Research Resources
National Center for Research Resources
6701 Democracy Boulevard
Room 906, MSC 4874
Bethesda, MD 20892
Telephone: (301) 435 0791
Email: [email protected]
3.B. Sending an
Application to the NIH
Applications must be
prepared using the research grant applications found in the PHS 398
instructions for preparing a research grant application. Submit a signed,
typewritten original of the application, including the checklist, and three signed photocopies in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express
or regular mail)
Bethesda, MD 20817 (for express/courier service;
non-USPS service)
Phone: (301) 435-0715
Personal deliveries of
applications are no longer permitted (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
At the time of
submission, two additional copies of the application must be sent to:
Office of Review
National Center for Research Resources
National Institutes of Health
6701 Democracy Blvd., Room 1001
Bethesda, MD 20892-4874 (Regular mail)
Bethesda, MD 20817 (FedEx or courier)
Phone: (301) 435-0811
Using the RFA Label: The RFA label available in
the PHS 398 application instructions must be affixed to the bottom of the face
page of the application. Type the RFA number on the label. Failure to use this
label could result in delayed processing of the application such that it may
not reach the review committee in time for review. In addition, the RFA title
and number must be typed on line 2 of the face page of the application form and
the YES box must be marked. The RFA label is also available at: http://grants.nih.gov/grants/funding/phs398/labels.pdf.
3.C. Application
Processing
Applications must be received on or before the
application receipt date(s) described above (Section IV.3.A.).
If an application is received after that date, it will be returned to the
applicant without review. Upon receipt, applications will be evaluated for
completeness by the CSR and responsiveness by the NCRR. Incomplete and non-responsive
applications will not be reviewed. Incomplete or unresponsive applications will not be
reviewed. Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within eight (8) weeks.
The NIH will not accept
any application in response to this funding opportunity that is essentially the
same as one currently pending initial review, unless the applicant withdraws
the pending application.
Information on the status of an application should be
checked by the Principal Investigator in the eRA Commons at: https://commons.era.nih.gov/commons/.
4. Intergovernmental Review
This initiative is not
subject to intergovernmental
review.
5. Funding Restrictions
All NIH awards are
subject to the terms and conditions, cost principles, and other considerations
described in the NIH Grants Policy Statement. The Grants Policy Statement can
be found at http://grants.nih.gov/grants/policy/policy.htm.
Pre-Award Costs: With the
exception of a T32 component, Pre-Award Costs are allowable. A grantee may, at
its own risk and without NIH prior approval, incur obligations and expenditures
to cover costs up to 90 days before the beginning date of the initial budget
period of a new or competing continuation award if such costs: are necessary to
conduct the project, and would be allowable under the grant, if awarded,
without NIH prior approval. If specific expenditures would otherwise require
prior approval, the grantee must obtain NIH approval before incurring the cost.
NIH prior approval is required for any costs to be incurred more than 90 days
before the beginning date of the initial budget period of a new or competing
continuation award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. See NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part6.htm.
Program budget: This should be constructed using the following general guidelines. Note that the TOTAL cost budget may not exceed the maximum allowed ($6M) in addition to the combined total costs of certain NIH awards (NCRR K12, K30, M01 and Roadmap T32 and K12) held by the applicant institution and its affiliates as stated as Approved Budget in the last Notice of Grant Award issued prior to 10/1/06 . There can be more than 1 award of each type of mechanism included in the CTSA, but only 1 CTSA for each Institution. Revised applications should use the NIH award budget base of the previous, unsuccessful. Applicants submitting revised applications who hold NCRR awards that will end during the application process should consult NCRR Program Staff prior to the project end date. Most items in the program will be listed on pages 4 & 5 of the PHS 398 for the U54 budget including:
Salary and fringe benefits for the CTSA PI, CTSA co-PI (if any), component directors(s) or co-director(s), professional and administrative staff, etc (personnel category of PHS 398 pages 4 & 5).
Research education component (excluding K12 and T32 components; other expenses category of PHS 398 pages 4 & 5).
Consultant costs, Equipment, Supplies, Travel, Patient care costs, Alterations, Other expenses, Consortium/contractual costs.
Applicants may request funds to support pilot research projects. These funds can be used for research expenses, such as supplies, equipment, and technical personnel.
Funds requested for payment to a hospital for Participant and Clinical Interaction resources shall be requested on PHS 398-Form Page 4, as Patient Care Costs. If there is a negotiated Research Patient Care Rate Agreement established between the hospital and DHHS that will be applied to the provision of CTSA services, include a copy of that agreement with the application. Categories for which F&A costs are included in the negotiated research patient care agreement should be excluded from F&A costs in the U54 budget (i.e., F&A costs may not be charged twice.)
Awards will be made on the basis of Total Cost Commitment. Awardees can request the transfer of awarded funds between the U54 (approved Institutional indirect costs) and K12 (8% indirect costs) components. No component of a CTSA award will have automatic carryover authority. Approved fund transfers and carryovers will be provided in award notices.
5.1 Specific Instructions and Limitations Related to the Research Education, Training and Career Development Components
5.1.1 Research Education Component
Research Education, but not T32 or K12, education costs should be placed on the U54 budget pages. These might include, but are not limited to: 1) curriculum and degree granting elements including costs to develop and provide lectures, courses, seminar series, etc.; 2) programs to provide research educational experiences to undergraduate students, allied health professionals such as study coordinators and project managers, and non-doctoral master's students (such as Masters in Clinical Research obtained after a MD or DDS degree, etc.); 3) a faculty core to provide mentor support and training in mentoring, leadership, research and laboratory management, and research team building skills. Mentors may receive up to $3,000 per year per pre-doctoral trainee and $10,000 per year per career development scholar to help defray laboratory or other research related expenses associated with hosting a trainee or scholar. Trainee stipends and K12 scholar salaries are not allowable costs for the Research Education Component. However, under certain circumstances subsistence allowances may be permitted for other program participants.
5.1.2 Mentored Career Development Component-K12
The NIH will also help defray the costs for the following expenses: (1) tuition and fees related to career development; (2) travel for scholars to the annual NIH meeting; (3) travel to one additional training or scientific meeting per year; (4) recruitment costs (up to $3,000 per year for costs such as brochures, recruitment-related travel, etc.) to attract participants who can excel in, and potentially become leaders in, clinical research. All costs of an existing RM K12, including infrastructure, will remain with the K12 component of the CTSA.
5.1.3. Predoctoral Research Training Component-T32
Allowable costs for each Predoctoral trainee for a 12-month appointment period include:
Stipend
A stipend is provided as a subsistence allowance to help trainees defray living expenses during the research training experience. It is not provided as a condition of employment with either the Federal Government or the awardee institution. Stipends must be paid to all trainees at the levels approved by the Secretary of the Department of Health and Human Services. The NIH will provide stipends for each predoctoral trainee position selected for the predoctoral research training component according to the appropriate fiscal year predoctoral NRSA stipend schedule. Stipend levels are adjusted periodically. The current NRSA stipend schedule can be found on the NIH Web site at: http://grants.nih.gov/training/nrsa.htm. The total stipend must be based on a 12-month appointment. No departure from the established stipend schedule may be negotiated by the institution with the trainee. The grantee institution is allowed to provide funds to an individual in addition to the stipends paid. Such funds may be provided either in the form of stipend supplementation from non-federal funds, or in the form of compensation such as salary or tuition remission for services provided by the trainee such as teaching or serving as a laboratory assistant. Under no circumstances may the conditions of stipend supplementation or the services provided for compensation interfere with, detract from, or prolong the trainee's approved NRSA training program.
Tuition, Fees, and Health Insurance
The NIH will offset the combined cost of tuition, fees, and health insurance (either self-only or family as appropriate) at the current rates as published at http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part10.htm#_Toc5460018, and as modified by NOT-OD-06-090 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-090.html)..
Trainee Travel
Up to $1000 for trainee travel, including attendance at scientific meetings that the institution determines to be necessary to the individual's research training, is allowable.
Training-Related Expenses (to include health insurance)
Institutional costs of $4,200 a year per predoctoral trainee may be requested to help defray the costs of other research training related expenses, such as health insurance (self-only or family, as appropriate), staff salaries, consultant costs, equipment, research supplies, and travel expenses for the training faculty. Under exceptional circumstances, which can include providing accommodations for a trainee with disabilities, it is possible to request institutional costs above the standard rate. Requests for additional trainee costs must be explained in detail and carefully justified in the application. Training related expenses may be adjusted in future fiscal years.
Facilities and Administrative Costs
A facilities and administrative allowance (indirect cost allowance) based on 8 percent of total allowable direct costs (this excludes amounts for tuition, fees and equipment) may be requested. See NRSA Policy Guidelines on the NIH Web site at: http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part11.htm and NOT-OD-06-090 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-090.html).
Concurrent Awards: An NRSA may not be held concurrently with another federally sponsored fellowship or similar Federal award that provides a stipend or otherwise duplicates provisions of the NRSA.
Taxability of Stipends: Internal Revenue Code Section 117 applies to the tax treatment of all scholarships and fellowships. The Tax Reform Act of 1986, Public Law 99-514, impacts on the tax liability of all individuals supported under the NRSA program. Under that section, non-degree candidates are now required to report as gross income all stipends and any monies paid on their behalf for course tuition and fees required for attendance. Degree candidates may exclude from gross income (for tax purposes) any amount used for tuition and related expenses such as fees, books, supplies, and equipment required for courses of instruction at a qualified educational organization.
The IRS and Treasury Department released regulations in January 2005 (Revenue Procedure 2005-11) clarifying the student exception to the FICA (Social Security and Medicare) taxes for students employed by a school, college, or university where the student is pursuing a course of study. Our understanding is that these final regulations do not apply to or impact Kirschstein-NRSA programs or awards. An NRSA stipend is provided by the NIH as a subsistence allowance for Kirschstein-NRSA fellows and trainees to help defray living expenses during the research training experience. NRSA recipients are not considered employees of the Federal government or the grantee institution for purposes of the award. We must note that NIH takes no position on the status of a particular taxpayer, nor does it have the authority to dispense tax advice. The interpretation and implementation of the tax laws are the domain of the IRS.
Individuals should consult their local IRS office about the applicability of the tax laws to their situation and for information on their tax obligation.
5.2. Plans for support beyond 5 years:
NIH is planning for an
additional 5 year competitive renewal of these awards. NIH support beyond the
initial five-year project period is not guaranteed and is dependent upon the
availability of appropriated funds, and success in any competition for renewed
support. In the event that there is no further support, no phase-out funds will
be provided. Thus, the applicant institution(s) must have plans in place to
provide continued support to remaining trainees in the event that funding from
the NIH is not available.
6. Other Submission Requirements
This Program is not subject
to the streamlined non-competing application process (SNAP). In general, this
means that all reporting of budgetary information and Program progress is
provided in greater detail in an annual progress report.
Plan for Sharing Research
Data
Data sharing is a
requirement of this RFA and the data sharing plan should be included in the
description of the CTSA Governance. The precise content of the data-sharing
plan will vary, depending on the data being collected. The applicant may wish
to describe briefly the expected schedule for data sharing, the format of the
final dataset, the documentation to be provided, whether or not any analytic
tools also will be provided, whether or not a data-sharing agreement will be
required and, if so, a brief description of such an agreement (including the
criteria for deciding who can receive the data and whether or not any
conditions will be placed on their use), and the mode of data sharing.
References to data sharing may also be appropriate in other sections of the
application.
All applicants must include a plan for sharing research data in their application. The data sharing policy is available at http://grants.nih.gov/grants/policy/data_sharing. All investigators responding to this funding opportunity should include a description of how final research data will be shared, or explain why data sharing is not possible. The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers and will be factored into the determination of scientific merit or the priority score.
Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication. NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm and http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part7.htm#_Toc54600131. Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
Program staff when making recommendations about funding applications will consider the adequacy of the resources-sharing plan and the related data-sharing plan. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report. (PHS 2590). See Section VI.3. Reporting. Plans for the development of research resources for use by the biomedical community should have appropriate timelines and mileposts.
The application must include clear written commitments from the officials responsible for intellectual property issues at all of the applicant institutions and their sub-contractors, to the effect that the institution(s) supports and agrees to abide by the research resource dissemination plans put forth in the application. A separate letter should be sent by each participating organization including each subcontractor. Lack of such letters will result in withdrawing the application as non-responsive. Additionally, peer reviewers, program staff, and advisors will evaluate the adequacy of dissemination plans prior to award (see below). Please note that institutional sign-off on the grant application signifies that all relevant components of the institution(s), including the technology transfer office(s), have reviewed and approved the document.
The initial review group will comment on the appropriateness of the proposed plan for data and resources dissemination. Program staff and advisors will also consider the adequacy of the dissemination plan as one of the criteria for award. The proposed sharing plan, after negotiation with the applicant when necessary, will be made a condition of the award. Evaluation of competing renewal application and annual non-competing progress reports will include assessment of the responsiveness to NIH guidelines of data, materials, methods, and software dissemination practice by the grantee.
Plan for Sharing Software
An additional software dissemination plan, with appropriate timelines, must be included in the description of the CTSA Governance. There is no prescribed single license for software produced in this project. However, NIH does have goals for software dissemination, and reviewers will be instructed to evaluate the dissemination plan relative to these goals:
1. The software should be freely available to biomedical researchers, educators, and institutions in the non-profit sector, such as institutions of education, research institutions, and government laboratories.
2. The terms of software availability should permit the commercialization of enhanced or customized versions of the software, or incorporation of the software or pieces of it into other software packages.
3. The
terms of software availability should include the ability of research
institutions outside the CTSA to modify the source code and to share
modifications with other colleagues as well as with the CTSA.
Section
V. Application Review Information
1. Criteria
The following will be
considered in making funding decisions:
The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health. In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposal will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.
Overall Evaluation: All components of the unified CTSA application, i.e., all related sections of the single overall application that are received as a unit, will be awarded a single overall priority score determined after evaluation of all components. Reviewers will be asked to summarize the overall strengths and weaknesses of the application, focusing particularly on the anticipated impact of the proposed CTSA on the quality of clinical and translational science at the applicant institutions. The overall evaluation will also ask whether the CTSA resources will be distributed equitably among different disciplines (e.g., medicine, pediatrics, pre-clinical research, etc.). Does the applicant acknowledge potential problem areas and consider alternative tactics? Is the institutional commitment appropriate?
Significance: Will the proposed CTSA significantly impact the overall quality of clinical and translational science at the applicant institution? Is the overall program vision and strategy adequate to satisfy the intent of this initiative to facilitate and sustain a home for clinical and translational science that incorporates a wide range of clinical disciplines, specialties, and sub-specialties? Will there be value added by the proposed C/D/I to the multidisciplinary translational research of its members? Will the proposed CTSA have potential to make significant contributions to a national consortium of CTSAs?
Approach: Will the CTSA program enhance, complement, or extend the applicant's current resources for clinical and translational science research? Does the application identify key obstacles to the performance of translational and clinical research and then propose plans or means to overcome these? Will the proposed C/D/I include relevant scientific disciplines to maximize productivity? Does the application make efficient use of potentially unique resources, such as access to certain human subject populations or the provision of pre-clinical resources? Does the applicant indicate how the organization will be adapted to respond to changes in translational focus? Will new opportunities for careers in clinical research arise across the spectrum of clinical and translational science?
CTSA Governance: Have the applicants described an effective administration and governance structure that will promote the discipline of clinical and translational science? Will an Advisory Committee be constituted to provide critical, stimulating, and thoughtful advice for the overall CTSA performance and CTSA Key functions? Are there plans to implement recommendations?
Implementation Plans: Is an implementation phase well described? Is the timeline for implementation feasible and are specific goals and milestones set? Are alternatives proposed should the goals and milestones not be reached in a timely manner? Is there a feasible time line for integrating CTSA resources with other complementary resources available to the institution?
Integration: How well will the components of the CTSA be integrated with each other? Are there plans to integrate CTSA activities into all the relevant schools that participate in clinical and translational science in the applicant institution? Is there a commitment to integrate the CTSA into the institution and into a national network of CTSAs and also to reach out to the local community? Will this integration be reflected in the senior leadership and decision-making processes of the CTSA? Is the CTSA program integrated, cohesive, synergistic, adaptable, and potentially more effective than what currently exists?
Local and National Collaboration, Data Sharing, and Dissemination: How adequately will the institution and its researchers collaborate, share and disseminate resource tools and resources at institutional, community, and national levels? Are plans included to address regulatory hurdles locally? Is there a commitment to and plans for adopting and implementing national standards?
Innovation: Is the CTSA program original and innovative? Are new approaches proposed that would integrate clinical, basic and other relevant (e.g. public health, bioinformatics) disciplines? Does the program develop or employ novel concepts, approaches, methodologies, tools, or technologies that will improve the discipline? Is the program likely to develop novel approaches to increasing the ease and efficiency of clinical and translational research, allowing research results to move from patient observations and laboratory discoveries to the bedside and to clinical practice?
Investigators: Does the PI have the experience and authority and committed time to administer the proposed institutional home for clinical and translational research? Will the PI have sufficient authority and credibility in the institution to work across institutional boundaries? Will the PI have the environment and institutional support necessary to be responsible for the resources committed by the institution(s) for the C/D/I? Does the program leadership and management team bring complementary and integrated expertise to the project?
Will the proposed C/D/I have the professional staffing to impact significantly the overall quality of clinical and translational science at the institution? If part of the proposal, do the Key Function Directors have the appropriate training, experience and resources to assume leadership roles? Have the Directors of the Key Functions committed sufficient time to this Program? Will the Directors have the authority to implement best practices identified at Steering Committees at their Institution? Are the administrative and professional staff appropriately trained and well suited to carry out this work?
Environment: Does the applicant adequately demonstrate that a program for awarding higher degrees in clinical research is in place? Do the academic and scientific environments contribute to the probability of success in establishing a home for clinical and translational science? Is there a strong training record at both institutional and faculty levels? Does the proposal provide strong evidence that the addition of the CTSA will provide resources that would not otherwise be possible? If applicable, are there adequate cooperative arrangements between affiliated institutions to ensure that the CTSA program performs effectively as one activity across institutional boundaries? Are there unique features of the scientific environment or in the available human subject populations or collaborative arrangements?
2.A. Additional Review Criteria:
In addition to the above criteria, the following components of the CTSA application will be considered in the determination of the overall priority score for the entire U54 application.
Institutional Commitment: Is there institutional commitment to establishing the CTSA program as an integral part of its overall clinical research environment? Will the institution align or adjust incentives and rewards to promote the academic mission and new modes of team-based research? Is there substantial commitment from the institutional leadership to protect the time of the investigators to pursue clinical and translational research and mitigate the demands of providing patient care? Will clinical researchers/trainees career development be supported in terms of a specific tenure process for clinical researchers at the institution? Is the institutional leadership committed to this program and its goals in terms of providing specific assets for the program, such as financial support, faculty support, specific equipment, dedicated space, or tuition rebates, as a few examples? Will existing NIH-supported Cores be appropriately shared with the CTSA program?
Development of Novel Clinical and Translational Methodologies: Is there an active program of research in novel methodologies? Is the outcome likely to benefit the C/D/I? Is there a plan to involve new investigators? Will these activities be integrated with the CTSA as a whole?
Pilot and Collaborative Translational and Clinical Studies: Is there an adequate plan to solicit proposals, to prioritize the projects and to review their methodology and research performance? Will the expected benefits to the CTSA and to the wider research community be measured and tracked? Will lessons learned be shared?
Biomedical Informatics: Will the biomedical informatics resources offered be commensurate with the breadth of the CTSA program? Will data security and privacy be safeguarded? Are assessments of performance of this resource included? Will the Biomedical Informatics Director have the necessary authority to the ensure implementation of best practices as adopted by the Biomedical Informatics Steering Committee? As applicable, will this resource be sufficient for intra- and inter-institutional operations? Will the institution be willing to work toward interoperability of the informatics systems and adopting national data standards?
Design, Biostatistics, and Clinical Research Ethics: What types of support and resources will be in place to ensure all clinical and translational research designs are sound and that statistical analyses are appropriate and rigorous? Will this training include conflict of interest, federal codes requirements, guaranteeing privacy and safety of research participants, especially as pertaining to vulnerable populations? Are there plans for creation and innovation in developing the application of these topics to clinical research? As applicable, will this resource be sufficient for intra- and inter-institutional operations?
Regulatory Knowledge and Support: Will this resource provide researcher-focused support for regulatory compliance and management? Is the resource well integrated with biomedical informatics and participant and clinical interactions? Is there duplication of IRB responsibilities? Does the institution have experience in working with multi-site trials and with the FDA with respect to studies involving investigational new drug application procedures? Will CTSA staff members be available with the necessary experience in working with the FDA and in ensuring that standards for reporting adverse events are met? Are criteria for identifying a research participant advocate sound?
Participant and Clinical Interactions: Will human subject participation in clinical research protocols be encouraged? Will the institution work with underserved populations in clinical research? Has the applicant adequately described and justified the resources to be provided? Will PCI resources meet the highest standards for subject safety, quality of science and statistical and ethical design? Is the application of Good Clinical Practice guidelines appropriate? Will resource utilization be tracked and are mechanisms proposed to adapt resources to the needs of investigators? Will the resources provided serve small as well as large studies or trials?
Community engagement and research: Will this effectively involve the community in which the CTSA institution resides, both the public and practitioners, in clinical and translational research priority setting, participation, and follow-up? Are there adequate plans to train researchers, trainees, and scholars in the methodology of community/population-based research and outreach? Will the resource foster long-term bidirectional relationships between the CTSA institution and the community for their mutual benefit? Will the research interests of CDI faculty contribute to an intellectually stimulating environment?
Translational Technologies and Resources: Is the plan to identify technologies to be offered appropriate? Will resource utilization and evaluation be adequate? Is their flexibility in types of resources to be offered? Will faculty members be encouraged to pursue research in areas that develop translational methodologies?
Research Education and Career Development: Do the Research Education, Training and Career Development components strengthen the training and career pathways for all clinical and translational research professionals and team members? Can increased efficiency shorten the period of training? Does the institution have a sufficient pool of academically strong trainees and commensurate experienced and well-qualified mentors to justify the career development pathways that are proposed? Will the curricula and courses proposed provide appropriate training in clinical and translational research relevant to a broad range of specialties? How will trainee registration for higher degrees in clinical research be encouraged? Has the Program Director committed adequate time to program administration?
Research Education Component: Review considerations include the quality, innovation and content of courses and adequacy of the syllabus; the scientific qualifications and experience of the faculty; the criteria for selecting participants; efforts to publicize the availability of the program to potential participants.
Pre-doctoral Research Training Component (T32): The quality of the proposed training program will be considered as well as whether the requested number of trainee positions is appropriate for the planned research training program. Does the proposed training program provide appropriate courses for clinical and translational science research? Are appropriate programmatic activities incorporated into the training program?
Research Training Record: This criterion evaluates the past research training record of both the program and the designated mentors. How successful are former trainees in seeking further career development and in establishing productive scientific careers? Evidence of further career development can include successful completion of the Ph.D., receipt of fellowships, career development awards, additional training appointments, and similar accomplishments. Evidence of a productive scientific career can include a record of successful competition for research grants, receipt of special honors or awards, a record of publications, receipt of patents, promotion to scientific positions, and any other measure of success consistent with the nature and duration of the training received. What is the track record of the mentors in directing pre-doctoral training or the potential of those mentors lacking a track record?
Mentored Career Development (K12) and Research Program Design: This criterion will assess the likelihood that the proposed career development and research plans will contribute significantly to the scientific development of the candidate scholars to successfully pursue clinical and translational research careers. Reviewers will evaluate whether the proposed plans include appropriate course work and/or activities to achieve program goals. The scientific quality, technical merit and degree of relevance of the proposed research projects the scholars will be pursuing will be evaluated.
Training (T32) and Career Development (K12): In addition to the above criteria, reviewers will be asked to comment on the following criteria for both the pre-doctoral (T32) and the career development (K12) programs.
Preceptors/Mentors: This criterion assesses the caliber of mentors as researchers, including successful competition for research support in areas directly related to the proposed research training or career development program. What is the overall quality of mentors' research, their publication record, and their successful competition for research support in areas directly related to the proposed training program? How strong is their record as mentors?
Institutional Training Environment and Commitment to the Program: For the training program, this criterion assesses the quality of the institutional training environment for NRSA supported trainees and the relationship of the NRSA program to the broader training program (if appropriate). What is the level of institutional commitment, quality of the facilities, availability of appropriate courses, and the availability of research and research training support? Does the environment in which the training program will be conducted, i.e. the quality of the participating departments and the extent of their participation, contribute to the probability of success? Is there evidence of adequate institutional commitment?
For the career development program, this criterion will assess the applicant institution's commitment to the program, such as recruitment efforts, necessary educational resources and equipment, and available established investigators who will serve as mentors, evidence that scholars will have sufficient protected time to devote to the program.
Trainee Recruitment, Selection and Retention: This criterion evaluates the quality of the applicant pool and the plan for selection of individuals for appointment to the training or career development program. Specifically, what is the quality and size of the applicant pool? Are the recruiting procedures, trainee selection criteria, and retention strategies appropriate and well defined?
Evaluation and Tracking of Research Education, Training & Career Development: Is the plan adequate to determine progress and outcome measures for each of the research education, training and career development components? Does it include a system for tracking participants following program completion to determine success or failure of the program? The tracking would include information on program publications; grant proposals and awards, and career trajectory of the trainees that were supported in the program. If an Advisory Committee is proposed, are plans adequate and appropriate to ensure proper monitoring of the research education, training and career development components? Are there means to modify the research education, training and career development components based on appropriate recommendations from the Advisory Committee?
Training in the Responsible Conduct of Research: Peer reviewers will assess the applicant's plans for training in the responsible conduct of research on the basis of the appropriateness of topics, format, amount and nature of faculty participation, and the frequency and duration of instruction for the research education, training and career development components.
Plans will be discussed after the overall determination of merit, and the review panel's evaluation of the plan will not be a factor in the determination of the priority score. Plans will be judged as acceptable or unacceptable. The acceptability of the plan will be described in an administrative note on the summary statement. Regardless of the priority score, applications with unacceptable plans will not be funded until the applicant provides a revised, acceptable plan. Program staff will judge the acceptability of the revised plan.
Recruitment and Retention Plan to Enhance Diversity: The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences workforce. The NIH expects efforts to diversify the workforce to lead to the recruitment of the most talented researchers from all groups; to improve the quality of the educational and training environment; to balance and broaden the perspective in setting research priorities; to improve the ability to recruit subjects from diverse backgrounds into clinical research protocols; and to improve the Nation’s capacity to address and eliminate health disparities.
Accordingly the NIH continues to encourage institutions to diversify their student and faculty populations and thus to increase the participation of individuals currently underrepresented in the biomedical, clinical, behavioral, and social sciences such as: individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have inhibited their ability to pursue a career in health-related research. Institutions are encouraged to identify candidates who will increase diversity on a national or institutional basis.
Peer reviewers will separately evaluate the recruitment and retention plan to enhance diversity after the overall score has been determined. Reviewers will examine the strategies to be used in the recruitment and retention of individuals from underrepresented groups. The review panel’s evaluation will be included in an administrative note in the summary statement. If the diversity recruitment and retention plan is judged to be unacceptable, funding will be withheld until a revised plan (and report) that addresses the deficiencies is received. Staff within the NIH awarding component, with guidance from the appropriate national advisory committee or council, will determine whether amended plans and reports submitted after the initial review are acceptable.
Evaluation Plan: Is the plan adequate to evaluate the short and long-term goals for each of the key proposed functions? Are the measures valid for the programs' goals to be assessed and how accessible and practical are the available data sources? Does the plan make sufficient resources available for participation in the national CTSA programs If necessary, is the plan to obtain IRB approval and informed consent from program participants adequate for self-evaluation activities and the national program evaluation?
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Inclusion of Women, Minorities and Children in Research: The adequacy of plans will be assessed as appropriate for the scientific goals of the research on the inclusion of subjects according to gender, all racial and ethnic groups (and subgroups), and children. Plans for the recruitment and retention of subjects also will be evaluated (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used, the five points described under Section F of the PHS Form 398 research grant application instructions must be included.
Biohazards:
If materials or procedures are proposed that are potentially hazardous to
research personnel and/or the environment, determine if the proposed
protections are adequate.
2.B. Additional Review
Considerations
Budget: The reasonableness of the
proposed budget and the requested period of support in relation to the proposed
research. Is the range of support to be provided appropriate to the
institution's environment, track record, and current and projected needs? Is
the proposed budget and requested period of support reasonable in relation to
the proposed research and size of the clinical research base, trainee pool, and
faculty expertise? The priority score will not be affected by the budget
evaluation.
2.C. Sharing Research Data
Data Sharing Plan: The reasonableness of the
data-sharing plan will be assessed by the reviewers and factored into the
determination of scientific merit or the priority score. The funding
organization will be responsible for monitoring the data sharing policy. http://grants.nih.gov/grants/policy/data_sharing.
The presence of a data-sharing plan will be part of the terms and conditions of
the award.
2.D. Sharing Research
Resources
NIH policy requires that
grant awardee recipients make unique research resources readily available for
research purposes to qualified individuals within the scientific community
after publication (See the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps/part_ii_5.htm#availofrr and
http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity
should include a sharing research resources plan addressing how unique research
resources will be shared or explain why sharing is not possible. The
reasonableness of the resources sharing plan or the rationale for not sharing
research resources will be assessed by the reviewers and factored into the
determination of scientific merit or the priority score.
The adequacy of the data and the resources sharing plan will be considered by
Program staff of the funding organization when making recommendations about
funding applications. Program staff may negotiate modifications of the data and
resource sharing plans with the Principal Investigator before recommending
funding of an application. The final version of the data and resource sharing
plans negotiated by both will become a condition of the award of the grant. The
effectiveness of the resource sharing will be evaluated as part of the
administrative review of each non-competing Grant Progress Report. (PHS 2590).
See Section VI.3. Reporting
3. Anticipated Announcement and Award Dates
Not applicable
Section
VI. Award Administration Information
1. Award Notices
After the peer review of
the application is completed, the PD/PI will be able to access his or her
Summary Statement (written critique) via the eRA Commons.
If the application is under consideration for funding,
NIH will request "just-in-time" information from the applicant. For
details, applicants may refer to the NIH Grants Policy Statement Part II: Terms
and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part4.htm).
A formal notification in the form of a Notice
of Award (NoA) will be provided to the applicant organization. The NoA
signed by the grants management officer is the authorizing document. Once all
administrative and programmatic issues have been resolved, the NoA will be generated
via email notification from the awarding component to the grantee business
official (designated in item 12 on the Application Face Page). If a grantee is
not email enabled, a hard copy of the NoA will be mailed to the business
official.
Selection of an application for award is not an
authorization to begin performance. Any costs incurred before receipt of the
NoA are at the recipient's risk. These costs may be reimbursed only to the
extent considered allowable pre-award costs. See Also Section
IV.5. Funding Restrictions.
At the time of an award decision, the U54 application will be disaggregated
into up to three separate yet administratively linked awards: the U54 and the
K12 and T32 (as applicable) awards. Each component will have a separate Notice
of Grant Award. The U54 award will reflect full F&A rate reimbursement
based upon the negotiated rate in effect at the time of award. The K12 and T32
awards will be subject to the 8 percent F&A rate reimbursement standard for
these mechanisms.
The budgetary recommendations of the peer review committee and programmatic considerations will be taken into account in developing a funding plan for successful applicants.
Research Education, Training and Career Development
Evaluation
In carrying out its stewardship of human resource-related programs, the NIH may begin requesting information essential to an assessment of the effectiveness of CTSA components. Accordingly, recipients of Research Education, Training and Career Development support through a CTSA are hereby notified that they may be contacted after the completion of this award for periodic updates on various aspects of their employment history, publications, support from research grants or contracts, honors and awards, professional activities, and other information helpful in evaluating the impact of the program.
Predoctoral Research Training Component-T32
Leave: Trainees supported by academic institutions should refer to the NIH NRSA guidelines at: http://grants.nih.gov/grants/guide/pa-files/PA-02-109.html for guidance regarding vacations and requested leave.
Carryover of un-obligated balances: The carryover of funds from one budget period to the next requires prior written approval of the NIH awarding component.
Change of Program Director: If change of a Program Director is necessary, support of the award is not automatic, but may be continued with NIH funding component prior approval, provided:
Changes of Program: Awards are made to a specific institution for a specific program under the guidance of a particular Program Director. Changes in any of these parameters require prior approval by NIH Program Staff. A rationale must be provided for any proposed changes in the aims of the original peer-reviewed program. Programmatic changes will be evaluated to ensure that the program remains within the scope of the original peer-reviewed application. If the new program does not satisfy this requirement, the T32 component of the cooperative agreement award will be terminated.
Transfer of Program: The research training component may not be transferred to another institution. If there are plans to alter or terminate the approved program, the NIH must be notified immediately to take appropriate actions.
Mentored Career Development Component-K12
Other Income: Awardees may retain royalties and fees for activities such as scholarly writing, service on advisory groups, honoraria from other institutions for lectures or seminars, fees resulting from clinical practice, professional consultation or other comparable activities, provided these activities remain incidental, are not required by the research and research-related activities of this award, and provided that the retention of such pay is consistent with the policies and practices of the grantee institution.
Usually, funds budgeted in an NIH supported research or research training grant for the salaries or fringe benefits of individuals, but freed as a result of a career award, may not be rebudgeted. The awarding component will give consideration to approval for the use of released funds only under unusual circumstances. Any proposed retention of funds released as a result of a career award must receive prior written approval of the NIH awarding component.
Special Leave: Under unusual and pressing circumstances, a scholar may submit a written request to the awarding component requesting a reduction in professional effort below 75 %. Such requests will be considered on a case-by-case basis during the award period. In no case will it be permissible to work at less than 50% effort. The nature of the circumstances requiring reduced effort might include medical conditions, disability, or pressing personal or family situations such as child or elder care. Permission to reduce the level of effort will not be approved to accommodate job opportunities, clinical practice, or clinical training. In each situation, the grantee institution must submit documentation supporting the need for reduced effort along with assurance of a continuing commitment to the scientific development of the scholar. In addition, the scholar must submit assurance of his/her intention to return to at least 75% effort as soon as possible. During the period of reduced effort, the salary and other costs supported by the award will be reduced accordingly.
Termination: When a grantee institution plans to terminate an award, the Grants Management Specialist listed on the Notice of Grant Award must be notified in writing at the earliest possible time so that appropriate instructions can be given for termination. The Director of the NIH may terminate an award upon determination that the purpose or terms of the award are not being fulfilled. In the event an award is terminated, NIH shall notify the grantee institution in writing of this determination, the reasons therefore, the effective date, and the right to appeal the decision.
Transfer of Program: The K12 component may not be transferred to another institution, and scholars who wish to move to another institution must terminate their support under the K12 program.
Changes
in Research Education and Career Development: Program Consultation with NIH
staff should occur if a significant change in the approved career development
program and/or research plan is being considered.
2. Administrative and National
Policy Requirements
All NIH grant and
cooperative agreement awards include the NIH Grants Policy Statement as part of
the NoA. For these terms of award, see the NIH Grants Policy Statement Part II:
Terms and Conditions of NIH Grant Awards, Subpart A: General (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part4.htm)
and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and
Conditions for Specific Types of Grants, Grantees, and Activities (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_part9.htm).
The following Terms and
Conditions will be incorporated into the award statement and will be provided
to the Principal Investigator as well as to the appropriate institutional
official, at the time of award.
2.A. Cooperative Agreement
Terms and Conditions of Award
The following special
terms of award are in addition to, and not in lieu of, otherwise applicable OMB
administrative guidelines, HHS grant administration regulations at 45 CFR Parts
74 and 92 (Part 92 is applicable when State and local Governments are eligible
to apply), and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for
this program will be the cooperative agreement (U54), an "assistance"
mechanism (rather than an "acquisition" mechanism), in which
substantial NIH programmatic involvement with the awardees is anticipated
during the performance of the activities. Under the cooperative agreement, the
NIH purpose is to support and stimulate the recipients' activities by
involvement in and otherwise working jointly with the award recipients in a
partnership role; it is not to assume direction, prime responsibility, or a
dominant role in the activities. Consistent with this concept, the dominant
role and prime responsibility resides with the awardees for the project as a
whole, although specific tasks and activities may be shared among the awardees
and the NIH as defined above.
2.A.1. Principal
Investigator Rights and Responsibilities
The Principal
Investigator will have the primary responsibility to define objectives and
approaches of the CTSA. The primary responsibilities of the awardees are to:
Principal
investigators and key personnel as appropriate are expected to participate in
annual Steering Committee meetings.
Awardees
will retain custody of and have primary rights to the data and software
developed under these awards, subject to Government rights of access consistent
with current HHS, PHS, and NIH policies.
2.A.2. NIH
Responsibilities
NIH Science
Officers will have substantial scientific involvement during the conduct of
this activity, through technical assistance, advice, and coordination above and
beyond normal program stewardship for grants. One or more Science Officers will
be assigned by the NIH CTSA Program Director to each CTSA Steering Committee,
including those constituted to address key functions. A given individual may
serve on more than one CTSA Steering Committee. NIH Science Officer(s) will:
To help carry out these duties, Science Officers may consult with non-NIH experts in the field.
NCRR Program Officers will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. The Program Officer will:
Additionally,
the NCRR CTSA Program Officer will be responsible for normal stewardship of the
award and may recommend the termination or curtailment of an investigator or
project/program (or an individual award) in the event the partnerships fail to
evolve within the intent and purpose of this initiative.
2.A.3. Collaborative
Responsibilities
A National CTSA Consortium
Steering Committee shall be established and composed of the PIs of each CTSA
and appropriate NIH Science Officers. A Chair will be selected by the Steering
Committee at an early meeting of the group from among the non-Federal members.
The Consortium Steering Committee will enlarge to accommodate new PIs of CTSAs
that are funded in future years and to accommodate the NIH Science Officers of
key-function-specific Steering sub-committees, as they are established. Each PI
will have one vote while the fraction of NIH Staff votes will be adjusted so it
does not exceed 33% of the Steering Committee.
The National CTSA Consortium Steering Committee shall be a forum for sharing policies, practices, and resources and for discussion of opportunities, impediments, joint agreement on broad issues impeding clinical research, government policies and practices, and other appropriate topics. The Committee will identify and approve best practices and policies that will advance clinical and translational research as a discipline and facilitate collaboration and sharing among CTSA institutions and with partners in clinical and translational research, e.g., industry, laboratories, hospitals.
Each CTSA institution must agree to work toward adopting and implementing the policies and best practices that are approved by the National CTSA Consortium Steering Committee.
CTSA Steering
sub-committees will be established for common themes identified by NIH (e.g.,
Research Education, Biomedical Informatics, Regulatory Affairs) and additional
sub-committees for key resources will be established as required. Membership of
these sub-committees will comprise the Directors of the corresponding key
functions at each CTSA, one member of the National CTSA Consortium Steering
Committee and one or more NIH Science Officers appointed by the NCRR CTSA
Program Director. A Chair will be selected by the Steering Committee at an
early meeting of the group from among the non-Federal members. Each full member
will have one vote with the fraction of NIH Staff votes will be adjusted so it
does not exceed 33% of the Steering sub-committee. The Chair will report
sub-committee recommendations regarding policies and best practices to the
National CTSA Consortium Steering Committee for approval.
2.A.4. Arbitration
Process
Any disagreements that
may arise in scientific or programmatic matters (within the scope of the award)
between award recipients and the NIH may be brought to arbitration. An
Arbitration Panel composed of three members will be convened. It will have
three members: a designee of the Steering Committee chosen without NIH staff
voting, one NIH designee, and a third designee with expertise in the relevant
area who is chosen by the other two; in the case of individual disagreement,
the first member may be chosen by the individual awardee. This special
arbitration procedure in no way affects the awardee's right to appeal an
adverse action that is otherwise appealable in accordance with PHS regulations
42 CFR Part 50, Subpart D and HHS regulations 45 CFR Part 16.
3. Reporting
The NIH will convene an
independent CTSA Evaluation Working Group to perform an evaluation of the
overall program. The awardees are expected to provide information that is
requested by the NIH for the evaluation process. The submission of this
material is expected to be electronic but may require submission of some paper.
1. Progress Reports
Awardees will be required to submit the PHS Non-Competing Grant Progress Report, Form 2590 annually (http://grants.nih.gov/grants/funding/2590/2590.htm) and financial statements as required in the NIH Grants Policy Statement. Progress reports are submitted using the Form PHS 2590, which can be obtained at the following website address: http://grants.nih.gov/grants/funding/2590/2590.htm. Forms are also available at most institutional offices of sponsored research. The report should provide information about changes in the Program and a summary report of any evaluations by External Advisors. These Annual Progress Reports will be closely monitored by NIH staff to ensure that the grant is achieving the goals of the Program. Since the Form PHS 2590 does not apply easily to this grant, adapt the application for continuation to contain the following information:
Predoctoral Research Training Component-T32: The NRSA instructions for the Non-Competing Grant Progress Report (Form 2590, starting on page 19) should be followed. The names and levels of those trainees who are continuing in the research-training program should be listed on Additional Form Page 5. Information on each trainee should also be included in the narrative portion of the progress report as described in the PHS Form 2590 instructions. An evaluation and tracking report as described in Section IV.2. of this announcement should be included annually as part of the Progress Report. Additional information that should be reported in concert with the PHS 2590 Progress Report instructions:
Financial Status Report (FSR): An annual FSR is required and must be submitted within 90 days of the end of each budget period for the T32 component of the U54 award. Continuation support will not be provided for this component until the required information is submitted and reviewed.
Trainee Reporting Requirements: The institution must submit a completed Statement of Appointment (PHS Form 2271) for each trainee appointed or reappointed to the training grant. This Form must be completed at the beginning of the initial appointment and annually thereafter. No funds may be provided until this document is submitted and accepted by the funding Institute.
Within 30 days of the end of the total support period for each trainee, the institution must submit a Termination Notice (PHS 416-7) to the NIH. Failure to submit the required forms in a timely, complete, and accurate manner may result in an expenditure disallowance or a delay in any continuation funding for the award. Forms may be found on the NIH Website at http://grants.nih.gov/grants/forms.htm.
There is no service payback obligation for current predoctoral trainees.
Mentored Career Development Component-K12 progress reports should include the following:
Provide Biographical sketches of new CTSA faculty and new mentors
Report Biomedical Informatics status, progress, problems, and solutions
Report Design, Biostatistics and Clinical Research ethics status, progress, problems, and solutions
Report Regulatory Support status, progress, problems, and solutions. Specific procedures or organizational components that lessen time or effort required to perform clinical research, or enhance the quality of clinical research
Report Participant and Clinical Interactions status, problems and solutions
Report any other resources added, describing status, progress, problems, and solutions
List of studies completed, ongoing, and planned, with brief descriptions, estimated cost, NIH Institute and Center focus, and progress.
Report status of the ongoing evaluation. Report information regarding self-evaluation activities and activities related to the national evaluation. Include:
a. Evaluation objectives to be addressed
b. Logic Model being used as a conceptual framework for the self-evaluation activities
c. Variables being measured
d. Data collection methods being employed (include instruments that were used)
e. Confidentiality and Human Subjects' Protection activities (include IRB protocols)
f. Interim findings
g. Timeline for future activities
h. Issues or barriers encountered
i. Roles and responsibilities in fulfilling the national evaluation requirements
List of publications from studies benefiting from CTSA resources, including trainees.
Report collaborative efforts among CTSA faculty, between CTSA faculty and other university faculty; between CTSA faculty and outside scientists
Additional
information will be required regarding Institutional support, Industry
involvement and support for HIV/AIDS-related studies, that will be announced
through a program website.
Awardees will be
required to submit the PHS Non-Competing Grant Progress Report, Form 2590
annually (http://grants.nih.gov/grants/funding/2590/2590.htm)
and financial statements as required in the NIH Grants Policy Statement.
Section
VII. Agency Contacts
We
encourage your inquiries concerning this funding opportunity and welcome the
opportunity to answer questions from potential applicants. Inquiries may fall
into three areas: scientific/research, peer review, and financial or grants
management issues:
1. Scientific/Research Contacts:
Dr. Anthony Hayward
Division
for Clinical Research Resources, NCRR
6701
Democracy Blvd
Room 906,
MCS 4874
Bethesda , MD 20892
Telephone:
(301) 435 0790
FAX:
(301) 480-3661
Email: [email protected]
2. Peer Review Contacts:
Dr. Sheryl Brining
Office of
Review, NCRR
6701
Democracy Blvd
Democracy
1, Room Number 1072
Bethesda , MD 20892
Telephone:
(301) 435-0811
FAX:
(301) 480-3660
Email: [email protected]
3. Financial or Grants Management Contacts:
Ms. Mary Niemiec
Office
for Grants Management, NCRR
6701
Democracy Blvd
Democracy
1, Room Number 1046
Bethesda , MD 20892|
Telephone:
(301) 435-0842
FAX:
(301) 480-3777
Email: [email protected]
Section
VIII. Other Information
Required Federal
Citations
Use of Animals in
Research:
Recipients of PHS
support for activities involving live, vertebrate animals must comply with PHS
Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable.
Human Subjects
Protection:
Federal regulations
(45CFR46) require that applications and proposals involving human subjects must
be evaluated with reference to the risks to the subjects, the adequacy of
protection against these risks, the potential benefits of the research to the
subjects and others, and the importance of the knowledge gained or to be gained
(http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety
Monitoring Plan:
Data and safety
monitoring is required for all types of clinical trials, including physiologic
toxicity and dose-finding studies (phase I); efficacy studies (Phase II);
efficacy, effectiveness and comparative trials (Phase III). Monitoring should
be commensurate with risk. The establishment of data and safety monitoring
boards (DSMBs) is required for multi-site clinical trials involving
interventions that entail potential risks to the participants (NIH Policy for
Data and Safety Monitoring, NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research
Data:
Investigators submitting
an NIH application seeking $500,000 or more in direct costs in any single year
are expected to include a plan for data sharing or state why this is not
possible (http://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their
institutions, on issues related to institutional policies and local IRB rules,
as well as local, State and Federal laws and regulations, including the Privacy
Rule. Reviewers will consider the data sharing plan but will not factor the
plan into the determination of the scientific merit or the priority score.
Access to Research
Data through the Freedom of Information Act:
The Office of Management
and Budget (OMB) Circular A-110 has been revised to provide access to research
data through the Freedom of Information Act (FOIA) under some circumstances.
Data that are (1) first produced in a project that is supported in whole or in
part with Federal funds and (2) cited publicly and officially by a Federal
agency in support of an action that has the force and effect of law (i.e., a
regulation) may be accessed through FOIA. It is important for applicants to
understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this funding opportunity in a
public archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the application.
In addition, applicants should think about how to structure informed consent
statements and other human subjects procedures given the potential for wider
use of data collected under this award.
Sharing of Model
Organisms:
NIH is committed to
support efforts that encourage sharing of important research resources
including the sharing of model organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm).
At the same time the NIH recognizes the rights of grantees and contractors to
elect and retain title to subject inventions developed with Federal funding
pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement http://grants.nih.gov/grants/policy/nihgps_2003/index.htm).
All investigators submitting an NIH application or contract proposal, beginning
with the October 1, 2004 receipt date, are expected to include in the
application/proposal a description of a specific plan for sharing and
distributing unique model organism research resources generated using NIH
funding or state why such sharing is restricted or not possible. This will
permit other researchers to benefit from the resources developed with public
funding. The inclusion of a model organism sharing plan is not subject to a
cost threshold in any year and is expected to be included in all applications
where the development of model organisms is anticipated.
Inclusion of Women
And Minorities in Clinical Research:
It is the policy of the
NIH that women and members of minority groups and their sub-populations must be
included in all NIH-supported clinical research projects unless a clear and
compelling justification is provided indicating that inclusion is inappropriate
with respect to the health of the subjects or the purpose of the research. This
policy results from the NIH Revitalization Act of 1993 (Section 492B of Public
Law 103-43). All investigators proposing clinical research should read the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a) all
applications or proposals and/or protocols must provide a description of plans
to conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and b)
investigators must report annual accrual and progress in conducting analyses,
as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children
as Participants in Clinical Research:
The NIH maintains a
policy that children (i.e., individuals under the age of 21) must be included
in all clinical research, conducted or supported by the NIH, unless there are
scientific and ethical reasons not to include them.
All investigators proposing research involving human
subjects should read the "NIH Policy and Guidelines" on the inclusion
of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).
Required Education on
the Protection of Human Subject Participants:
NIH policy requires
education on the protection of human subject participants for all investigators
submitting NIH applications for research involving human subjects and
individuals designated as key personnel. The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem
Cells (hESC):
Criteria for federal
funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.
Only research using hESC lines that are registered in the NIH Human Embryonic
Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility
of the applicant to provide in the project description and elsewhere in the
application as appropriate, the official NIH identifier(s) for the hESC
line(s)to be used in the proposed research. Applications that do not provide
this information will be returned without review.
NIH Public Access Policy:
NIH-funded investigators
are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov) at PubMed Central
(PMC) an electronic version of the author's final manuscript upon acceptance
for publication, resulting from research supported in whole or in part with
direct costs from NIH. The author's final manuscript is defined as the final
version accepted for journal publication, and includes all modifications from
the publishing peer review process.
NIH is requesting that
authors submit manuscripts resulting from 1) currently funded NIH research projects
or 2) previously supported NIH research projects if they are accepted for
publication on or after May 2, 2005. The NIH Public Access Policy applies to
all research grant and career development award mechanisms, cooperative
agreements, contracts, Institutional and Individual Ruth L. Kirschstein
National Research Service Awards, as well as NIH intramural research studies.
The Policy applies to peer-reviewed, original research publications that have
been supported in whole or in part with direct costs from NIH, but it does not
apply to book chapters, editorials, reviews, or conference proceedings.
Publications resulting from non-NIH-supported research projects should not be
submitted.
For more information
about the Policy or the submission process please visit the NIH Public Access Policy Web site at http://publicaccess.nih.gov/ and
view the Policy or other Resources and Tools including the Authors' Manual (http://publicaccess.nih.gov/publicaccess_Manual.htm).
Standards for Privacy
of Individually Identifiable Health Information:
The Department of Health
and Human Services (DHHS) issued final modification to the "Standards for
Privacy of Individually Identifiable Health Information", the
"Privacy Rule", on August 14, 2002 . The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable health
information, and is administered and enforced by the DHHS Office for Civil
Rights (OCR).
Decisions about applicability and implementation of
the Privacy Rule reside with the researcher and his/her institution. The OCR
website (http://www.hhs.gov/ocr/)
provides information on the Privacy Rule, including a complete Regulation Text
and a set of decision tools on "Am I a covered entity?" Information
on the impact of the HIPAA Privacy Rule on NIH processes involving the review,
funding, and progress monitoring of grants, cooperative agreements, and
research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant
Applications or Appendices:
All applications and proposals
for NIH funding must be self-contained within specified page limitations. For
publications listed in the appendix and/or Progress report, internet addresses
(URLs) must be used for publicly accessible on-line journal
articles. Unless otherwise specified in this solicitation,
Internet addresses (URLs) should not be used to provide any other information necessary for the review because reviewers are under no obligation
to view the Internet sites. Furthermore, we caution reviewers that their
anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health
Service (PHS) is committed to achieving the health promotion and disease
prevention objectives of "Healthy People 2010," a PHS-led national
activity for setting priority areas. This PA is related to one or more of the
priority areas. Potential applicants may obtain a copy of "Healthy People
2010" at http://www.health.gov/healthypeople.
Authority and
Regulations:
This program is described in
the Catalog of Federal Domestic Assistance at http://www.cfda.gov/
and is not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review. Awards are made under the
authorization of Sections 301 and 405 of the Public Health Service Act as
amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR
Parts 74 and 92. The National Research Service Award (T32) component is
supported under the authorization of Section 487 of the Public Health Service
Act as amended (42 USC 288) and under Federal Regulations 42 CFR 66. All awards
are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly
encourages all grant recipients to provide a smoke-free workplace and
discourage the use of all tobacco products. In addition, Public Law 103-227,
the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in
some cases, any portion of a facility) in which regular or routine education,
library, day care, health care, or early childhood development services are
provided to children. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
Loan Repayment
Programs:
NIH encourages
applications for educational loan repayment from qualified health professionals
who have made a commitment to pursue a research career involving clinical,
pediatric, contraception, infertility, and health disparities related areas.
The LRP is an important component of NIH's efforts to recruit and retain the
next generation of researchers by providing the means for developing a research
career unfettered by the burden of student loan debt. Note that an NIH grant is
not required for eligibility and concurrent career award and LRP applications
are encouraged. The periods of career award and LRP award may overlap providing
the LRP recipient with the required commitment of time and effort, as LRP
awardees must commit at least 50% of their time (at least 20 hours per week
based on a 40 hour week) for two years to the research. For further
information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||